IL284856A - DBAIT molecule in combination with a kinase inhibitor for cancer treatment - Google Patents

DBAIT molecule in combination with a kinase inhibitor for cancer treatment

Info

Publication number
IL284856A
IL284856A IL284856A IL28485621A IL284856A IL 284856 A IL284856 A IL 284856A IL 284856 A IL284856 A IL 284856A IL 28485621 A IL28485621 A IL 28485621A IL 284856 A IL284856 A IL 284856A
Authority
IL
Israel
Prior art keywords
cancer
treatment
combination
kinase inhibitor
dbait molecule
Prior art date
Application number
IL284856A
Other languages
English (en)
Hebrew (he)
Original Assignee
Onxeo
Inst Nat Sante Rech Med
• Univ Paul Sabatier Toulouse Iii
• Inst Claudius Regaud
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Onxeo, Inst Nat Sante Rech Med, • Univ Paul Sabatier Toulouse Iii, • Inst Claudius Regaud filed Critical Onxeo
Publication of IL284856A publication Critical patent/IL284856A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A61K47/544—Phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/13—Decoys
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3515—Lipophilic moiety, e.g. cholesterol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Botany (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL284856A 2019-03-21 2021-07-14 DBAIT molecule in combination with a kinase inhibitor for cancer treatment IL284856A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19305349 2019-03-21
PCT/EP2020/057555 WO2020188015A1 (en) 2019-03-21 2020-03-19 A dbait molecule in combination with kinase inhibitor for the treatment of cancer

Publications (1)

Publication Number Publication Date
IL284856A true IL284856A (en) 2021-08-31

Family

ID=66103004

Family Applications (1)

Application Number Title Priority Date Filing Date
IL284856A IL284856A (en) 2019-03-21 2021-07-14 DBAIT molecule in combination with a kinase inhibitor for cancer treatment

Country Status (12)

Country Link
US (1) US20220143049A1 (en])
EP (1) EP3942045A1 (en])
JP (1) JP2022526713A (en])
KR (1) KR20210142154A (en])
CN (1) CN114364798A (en])
AU (1) AU2020242287A1 (en])
BR (1) BR112021018168B1 (en])
CA (1) CA3129665A1 (en])
EA (1) EA202192575A1 (en])
IL (1) IL284856A (en])
MX (1) MX2021009863A (en])
WO (1) WO2020188015A1 (en])

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200130856A (ko) * 2018-03-13 2020-11-20 옹쎄오 암 치료에서 획득한 내성에 대한 디베이트 분자
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
KR102657354B1 (ko) * 2021-06-08 2024-04-15 한국과학기술원 Syk 저해제를 포함하는 대장암 예방 또는 치료용 병용투여 조성물
JP2025502748A (ja) 2021-12-30 2025-01-28 バイオメア フュージョン，インコーポレイテッド Ｆｌｔ３の阻害剤としてのピラジン化合物

Family Cites Families (637)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0003731A3 (en) 1997-07-01 2002-11-28 Warner Lambert Co 4-bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as mek inhibitors
US5932580A (en) 1997-12-01 1999-08-03 Yissum Research And Development Company Of The Hebrew University Of Jerusalem PDGF receptor kinase inhibitory compounds their preparation and compositions
ATE269295T1 (de) 1998-04-17 2004-07-15 Parker Hughes Inst Btk inhibitoren und verfahren zur identifizierung und verwendung
DE59903921D1 (de) 1998-05-04 2003-02-06 Zentaris Ag Indolderivate und deren verwendung zur behandlung von malignen und anderen, auf pathologischen zellproliferationen beruhenden erkrankungen
JP2002534498A (ja) 1999-01-13 2002-10-15 ワーナー−ランバート・カンパニー Ｍｅｋ阻害剤としてのベンゼンスルホンアミド誘導体およびその使用
CA2348236A1 (en) 1999-01-13 2000-07-20 Stephen Douglas Barrett 4-arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective mek inhibitors
DE69928697T2 (de) 1999-01-13 2006-06-22 Warner-Lambert Co. Llc Sulfohydroxamsäure and sulfohydroxamate und ihre verwendung als mek-inhibitoren
OA11746A (en) 1999-01-13 2005-05-13 Warner Lambert Co Benzoheterocycles and their use as MEK inhibitors.
CA2362380A1 (en) 1999-03-19 2000-09-28 Bristol-Meyers Squibb Pharma Company Amino-thio-acrylonitriles as mek inhibitors
GB9910577D0 (en) 1999-05-08 1999-07-07 Zeneca Ltd Chemical compounds
US6797706B1 (en) 1999-06-09 2004-09-28 Yamanouchi Pharmaceutical Co., Ltd. Heterocyclecarboxamide derivative
GB9918035D0 (en) 1999-07-30 1999-09-29 Novartis Ag Organic compounds
CA2384378C (en) 1999-10-06 2011-05-24 Boehringer Ingelheim Pharmaceuticals, Inc. Heterocyclic compounds useful as inhibitors of tyrosine kinases
UA74803C2 (uk) 1999-11-11 2006-02-15 Осі Фармасьютікалз, Інк. Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
CA2395593C (en) 1999-12-24 2011-08-02 Aventis Pharma Limited Azaindoles
AU2968701A (en) 2000-01-24 2001-07-31 Genzyme Corporation Jak/stat pathway inhibitors and the uses thereof
DE122008000002I1 (de) 2000-02-15 2008-04-17 Sugen Inc Pyrrol substituierte indolin-2-on protein kinase inhibitoren
US7087608B2 (en) 2000-03-03 2006-08-08 Robert Charles Atkins Use of PDGF receptor tyrosine kinase inhibitors for the treatment of diabetic nephropathy
AU2001247372A1 (en) 2000-03-15 2001-09-24 Warner Lambert Company 5-amide substituted diarylamines as mex inhibitors
AR028261A1 (es) 2000-03-28 2003-04-30 Wyeth Corp Inhibidores triciclicos de la proteina quinasa
AR035851A1 (es) 2000-03-28 2004-07-21 Wyeth Corp 3-cianoquinolinas, 3-ciano-1,6-naftiridinas y 3-ciano-1,7-naftiridinas como inhibidoras de proteina quinasas
DE10017480A1 (de) 2000-04-07 2001-10-11 Transmit Technologietransfer Verwendung von Substanzen, die als MEK Inhibitor wirken, zur Herstellung eines Arneimittels gegen DNA- und RNA-Viren
JP2001302667A (ja) 2000-04-28 2001-10-31 Bayer Ag イミダゾピリミジン誘導体およびトリアゾロピリミジン誘導体
WO2002069960A2 (en) 2001-03-06 2002-09-12 Axxima Pharmaceuticals Ag Use of mek inhibitors for treating inflammation and virus induced hemorrhagic shock
DE60231868D1 (de) 2001-04-24 2009-05-20 Purdue Research Foundation Folat-mimetika und deren folatrezeptorbindende konjugate
AR035885A1 (es) 2001-05-14 2004-07-21 Novartis Ag Derivados de 4-amino-5-fenil-7-ciclobutilpirrolo (2,3-d)pirimidina, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos derivados para la preparacion de una composicion farmaceutica
WO2003002114A2 (en) 2001-06-29 2003-01-09 Ab Science Use of potent, selective and non toxic c-kit inhibitors for treating mastocytosis
WO2003004006A2 (en) 2001-06-29 2003-01-16 Ab Science Use of potent, selective and non toxic c-kit inhibitors for treating tumor angiogenesis
CA2452368A1 (en) 2001-06-29 2003-01-09 Ab Science New potent, selective and non toxic c-kit inhibitors
DE60225590T2 (de) 2001-09-20 2008-09-25 Ab Science C-kithemmer zur behandlung von bakteriellen infektionen
WO2003027111A1 (en) 2001-09-27 2003-04-03 Smithkline Beecham Corporation Chemical compounds
US20030158195A1 (en) 2001-12-21 2003-08-21 Cywin Charles L. 1,6 naphthyridines useful as inhibitors of SYK kinase
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
WO2003077855A2 (en) 2002-03-13 2003-09-25 Array Biopharma, Inc N3 alkylated benzimidazole derivatives as mek inhibitors
US7235537B2 (en) 2002-03-13 2007-06-26 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
UA77765C2 (en) 2002-03-13 2007-01-15 Array Biopharma Inc N3 alkylated derivatives of benzimidazole as mek inhibitors
AU2003233946A1 (en) 2002-03-15 2003-09-29 Novartis Ag 4-(4-methylpiperazin-1-ylmethyl)-n-(4-methyl-3(4-pyridin-3-yl)pyrimidin-2-yl-amino)phenyl)-benzamide for treating ang ii-mediated diseases
ATE489384T1 (de) 2002-05-06 2010-12-15 Vertex Pharma Thiadiazole oder oxadiazole und ihre verwendung als jak proteinkinaseinhibitoren
US7122552B2 (en) 2002-05-30 2006-10-17 Vertex Pharmaceuticals Incorporated Inhibitors of JAK and CDK2 protein kinases
GB0215823D0 (en) 2002-07-09 2002-08-14 Astrazeneca Ab Quinazoline derivatives
AU2003281664A1 (en) 2002-07-25 2004-02-16 Pfizer Products Inc. Isothiazole derivatives useful as anticancer agents
KR101036866B1 (ko) 2002-08-02 2011-05-25 에이비 사이언스 2-(3-아미노아릴)아미노-4-아릴-티아졸 및 ｃ-ｋｉｔ억제제로서의 이의 용도
US7312227B2 (en) 2002-11-01 2007-12-25 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of JAK and other protein kinases
ES2289349T3 (es) 2002-11-04 2008-02-01 Vertex Pharmaceuticals Incorporated Derivados de heteroaril-pirimidina como inhibidores de jak.
JP2006508107A (ja) 2002-11-05 2006-03-09 バーテックス　ファーマシューティカルズ　インコーポレイテッド Ｊａｋおよび他のプロテインキナーゼのインヒビターとして有用な化合物
US7098332B2 (en) 2002-12-20 2006-08-29 Hoffmann-La Roche Inc. 5,8-Dihydro-6H-pyrido[2,3-d]pyrimidin-7-ones
ATE508747T1 (de) 2003-03-10 2011-05-15 Eisai R&D Man Co Ltd C-kit kinase-hemmer
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
EP1648455A4 (en) 2003-07-23 2009-03-04 Exelixis Inc MODULATORS OF ALK PROTEIN (ANAPLASTIC LYMPHOMA KINASE) AND METHODS OF USE
JP2007501238A (ja) 2003-08-01 2007-01-25 ワイス・ホールディングズ・コーポレイション 癌の治療および阻害のための上皮増殖因子受容体キナーゼ阻害剤と細胞障害性物質との組み合わせの使用
ES2380206T3 (es) 2003-08-15 2012-05-09 Novartis Ag 2,4-Pirimidindiaminas útiles para el tratamiento de enfermedades neoplásicas, trastornos inflamatorios y del sistema inmunitario
KR20060121818A (ko) 2003-08-21 2006-11-29 오에스아이 파마슈티컬스, 인코포레이티드 Ｎ-치환된 벤즈이미다졸릴 ｃ-ｋｉｔ 억제제
EP1664032B1 (en) 2003-08-21 2008-11-05 OSI Pharmaceuticals, Inc. N-substituted pyrazolyl-amidyl-benzimidazolyl c-kit inhibitors
CN1839132A (zh) 2003-08-21 2006-09-27 Osi制药公司 作为c－kit抑制剂的n3－取代的咪唑并吡啶衍生物
US7538120B2 (en) 2003-09-03 2009-05-26 Array Biopharma Inc. Method of treating inflammatory diseases
US7144907B2 (en) 2003-09-03 2006-12-05 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
DE10342794A1 (de) 2003-09-16 2005-04-21 Basf Ag Sekretion von Proteinen aus Hefen
GB0321710D0 (en) 2003-09-16 2003-10-15 Novartis Ag Organic compounds
TW200520745A (en) 2003-09-19 2005-07-01 Chugai Pharmaceutical Co Ltd Novel 4-phenylamino-benzaldoxime derivatives and uses thereof as mitogen-activated protein kinase kinase (MEK) inhibitors
EA200600495A1 (ru) 2003-09-23 2006-10-27 Новартис Аг Комбинация ингибитора vegf рецептора с химиотерапевтическим агентом
TW200530238A (en) 2003-10-15 2005-09-16 Osi Pharm Inc Imidazopyrazine tyrosine kinase inhibitors
US7476729B2 (en) 2003-10-24 2009-01-13 Institut Curie Dbait and uses thereof
EP1526177A1 (en) 2003-10-24 2005-04-27 Institut Curie Nucleic acids useful for triggering tumor cell lethality
MY141220A (en) 2003-11-17 2010-03-31 Astrazeneca Ab Pyrazole derivatives as inhibitors of receptor tyrosine kinases
ES2453367T3 (es) 2003-11-19 2014-04-07 Array Biopharma, Inc. Inhibidores heterocíclicos de MEK
DE102004001607A1 (de) 2004-01-09 2005-08-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittelkombinationen auf der Basis von Scopin- oder Tropensäureestern mit EGFR-Kinase-Hemmern
AU2005209485A1 (en) 2004-01-30 2005-08-11 Ab Science 2-(3-substituted-aryl)amino-4-aryl-thiazoles as tyrosine kinase inhibitors
JP4457108B2 (ja) 2004-02-27 2010-04-28 エーザイ・アール・アンド・ディー・マネジメント株式会社 新規ピリジン誘導体およびピリミジン誘導体（１）
PT2332940E (pt) 2004-03-30 2013-01-30 Vertex Pharma Azaindoles úteis como inibidores de jak e outras proteínas quinases
FR2868422B1 (fr) 2004-03-31 2006-07-14 Aventis Pharma Sa Nouveaux derives pyrrolo(2,3-b) pyridine, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
DK1740591T3 (da) 2004-04-02 2009-10-26 Osi Pharm Inc Heterobicykliske proteinkinaseinhibitorer substitueret med en 6,6-biocyclisk ring
WO2005123696A1 (en) 2004-06-15 2005-12-29 Astrazeneca Ab Substituted quinazolones as anti-cancer agents
TW200616974A (en) 2004-07-01 2006-06-01 Astrazeneca Ab Chemical compounds
EP1778224B1 (en) 2004-07-19 2014-03-26 The Johns-Hopkins University Flt3 inhibitors for immune suppression
TWI361066B (en) 2004-07-26 2012-04-01 Chugai Pharmaceutical Co Ltd 5-substituted-2-phenylamino benzamides as mek inhibitors
WO2007040469A2 (en) 2005-09-15 2007-04-12 Kosak Ken M Chloroquine coupled compositions and methods for their synthesis
CA2577275A1 (en) 2004-08-31 2006-03-09 Astrazeneca Ab Quinazolinone derivatives and their use as b-raf inhibitors
MX2007002433A (es) 2004-09-01 2007-05-04 Astrazeneca Ab Derivados de quinazolinona y su uso como inhibidores de b-raf.
PT1791830E (pt) 2004-09-17 2011-04-04 Vertex Pharma Compostos de diaminotriazole úteis como inibidores de proteína-quinase
CN101080396A (zh) 2004-10-15 2007-11-28 阿斯利康(瑞典)有限公司 作为B－Raf抑制剂的喹喔啉
BRPI0517887A (pt) 2004-11-24 2008-10-21 Novartis Ag combinações de inibidores de jaks
JP2008520615A (ja) 2004-11-24 2008-06-19 ラボラトワール セローノ ソシエテ アノニム 過増殖性障害を処置するためのｍｅｋ阻害剤としての新規４−アリールアミノピリドン誘導体
EP1831206B1 (en) 2004-12-01 2011-08-24 OSI Pharmaceuticals, Inc. N-substituted benzimidazolyl c-kit inhibitors and combinatorial benzimidazole library
ES2330872T3 (es) 2004-12-01 2009-12-16 Merck Serono Sa Derivados de (1,2,4)triazolo(4,3-a)piridina para el tratamiento de enfermedades hiperproliferativas.
AR054416A1 (es) 2004-12-22 2007-06-27 Incyte Corp Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas.
UY29300A1 (es) 2004-12-22 2006-07-31 Astrazeneca Ab Compuestos quimicos
CA2594708A1 (en) 2005-01-25 2006-08-03 Astrazeneca Ab Chemical compounds
CA2596527C (en) 2005-01-27 2013-02-12 Kyowa Hakko Kogyo Co., Ltd. Igf-1r inhibitors
SI2383268T1 (sl) 2005-02-04 2016-02-29 Astrazeneca Ab Derivati pirazolilaminopiridina uporabni kot kinazni inhibitorji
US8129403B2 (en) 2005-02-16 2012-03-06 Astrazeneca Ab Chemical compounds
EP1853602B1 (en) 2005-02-16 2010-07-14 AstraZeneca AB Chemical compounds
CA2599544A1 (en) 2005-02-28 2006-09-08 Japan Tobacco Inc. Novel aminopyridine compound with syk inhibitory activity
AU2006229343A1 (en) 2005-03-28 2006-10-05 Kirin Pharma Kabushiki Kaisha Thienopyridine derivative, or quinoline derivative, or quinazoline derivative, having c-Met autophosphorylation inhibiting potency
EP1874305B1 (en) 2005-04-04 2014-08-27 AB Science Substituted oxazole derivatives and their use as tyrosine kinase inhibitors
CA2610446A1 (en) 2005-04-19 2006-10-26 Kyowa Hakko Kogyo Co., Ltd. Nitrogen-containing heterocyclic compound
CA2608009A1 (en) 2005-05-16 2006-11-23 Astrazeneca Ab Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors
CN102304086B (zh) 2005-05-18 2013-12-04 阵列生物制药公司 Mek的杂环抑制剂及其使用方法
WO2006130673A1 (en) 2005-05-31 2006-12-07 Janssen Pharmaceutica, N.V. 3-benzoimidazolyl-pyrazolopyridines useful in treating kinase disorders
WO2006133417A1 (en) 2005-06-07 2006-12-14 Valeant Pharmaceuticals International Phenylamino isothiazole carboxamidines as mek inhibitors
US20070021435A1 (en) 2005-06-10 2007-01-25 Gaul Michael D Aminopyrimidines as kinase modulators
TW200738638A (en) 2005-06-23 2007-10-16 Merck & Co Inc Tyrosine kinase inhibitors
DK1896421T3 (da) 2005-06-23 2012-01-09 Merck Sharp & Dohme Benzocyclohetapyridiner som hæmmere af receptoren tyrosinkinase MET
TW200740820A (en) 2005-07-05 2007-11-01 Takeda Pharmaceuticals Co Fused heterocyclic derivatives and use thereof
CA2615291A1 (en) 2005-07-14 2007-01-18 Astellas Pharma Inc. Heterocyclic janus kinase 3 inhibitors
EP1904065A2 (en) 2005-07-14 2008-04-02 AB Science Use of dual c-kit/fgfr3 inhibitors for treating multiple myeloma
WO2007028445A1 (en) 2005-07-15 2007-03-15 Glaxo Group Limited 6-indolyl-4-yl-amino-5-halogeno-2-pyrimidinyl-amino derivatives
PE20070362A1 (es) 2005-07-15 2007-04-23 Glaxo Group Ltd COMPUESTOS DERIVADOS DE INDAZOL-4-IL-2,4-PIRIMIDINDIAMINA COMO INHIBIDORES DE TIROSINA QUINASA (QUINASA Syk)
AU2006272837B2 (en) 2005-07-21 2012-08-23 Ardea Biosciences, Inc. N-(arylamino)-sulfonamide inhibitors of MEK
HRP20130719T1 (en) 2005-08-24 2013-09-30 Eisai R&D Management Co., Ltd. Novel pyridine derivative and pyrimidine derivative (3)
US7884119B2 (en) 2005-09-07 2011-02-08 Rigel Pharmaceuticals, Inc. Triazole derivatives useful as Axl inhibitors
FR2891273B1 (fr) 2005-09-27 2007-11-23 Aventis Pharma Sa NOUVEAUX DERIVES BENZIMIDAZOLES ET BENZOTHIAZOLES, LEUR PREPARATION ET LEUR UTILISATION PHARMACEUTIQUE NOTAMMENT COMME INHIBITEURS DE CMet
JP5335426B2 (ja) 2005-09-27 2013-11-06 アイアールエム・リミテッド・ライアビリティ・カンパニー ジアリールアミン含有化合物および組成物、ならびにｃ−ｋｉｔ受容体のモジュレーターとしてのそれらの使用
KR20130058072A (ko) 2005-10-07 2013-06-03 엑셀리시스, 인코포레이티드 증식성 질환의 치료를 위한 ｍｅｋ 억제제로서의 아제티딘
AU2006301435A1 (en) 2005-10-13 2007-04-19 Glaxo Group Limited Pyrrolopyrimidine derivatives as Syk inhibitors
ES2402419T3 (es) 2005-12-05 2013-05-03 Pfizer Products Inc. Polimorfos de un inhibidor de C-MET/HGFR
PT2348023E (pt) 2005-12-13 2015-09-15 Incyte Corp Pirrolo[2,3-b] pirimidinas e pirrolo[2,3-b]piridinas substituídas com heteroarilo como inibidores de janus quinase
US20080299113A1 (en) 2005-12-19 2008-12-04 Arnold Lee D Combined treatment with and composition of 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitor and anti-cancer agents
EP1966155A1 (en) 2005-12-21 2008-09-10 AstraZeneca AB Tosylate salt of 6- (4-br0m0-2-chl0r0phenylamin0) -7-fluoro-n- (2-hydroxyethoxy) -3-methyl-3h-benzimi dazole- 5 - carboxamide , mek inhibitor useful in the treatment of cancer
JP2009520784A (ja) 2005-12-22 2009-05-28 アストラゼネカ アクチボラグ キナゾリン誘導体、その製造方法および抗癌剤としてのその使用
TWI423976B (zh) 2006-01-17 2014-01-21 Vertex Pharma 適合作為傑納斯激酶（ｊａｎｕｓ ｋｉｎａｓｅ）抑制劑之氮雜吲哚
FR2896503B1 (fr) 2006-01-23 2012-07-13 Aventis Pharma Sa Nouveaux derives soufres d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
FR2896504B1 (fr) 2006-01-23 2012-07-13 Aventis Pharma Sa Nouveaux derives d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
WO2007085540A1 (en) 2006-01-27 2007-08-02 Glaxo Group Limited 1h-indaz0l-4-yl-2 , 4-pyrimidinediamine derivatives
GB0601962D0 (en) 2006-01-31 2006-03-15 Ucb Sa Therapeutic agents
TW200740776A (en) 2006-02-06 2007-11-01 Osi Pharm Inc N-phenylbenzotriazolyl c-kit inhibitors
RU2008141761A (ru) 2006-03-22 2010-04-27 Вертекс Фармасьютикалз Инкорпорейтед (Us) ИНГИБИТОРЫ с-МЕТ ПРОТЕИНКИНАЗЫ
EP2007737A2 (en) 2006-04-05 2008-12-31 AstraZeneca AB Chemical compounds
CN101415689A (zh) 2006-04-05 2009-04-22 阿斯利康(瑞典)有限公司 具有抗癌活性的经取代的喹唑啉
WO2007117494A1 (en) 2006-04-05 2007-10-18 Vertex Pharmaceuticals Incorporated Deazapurines useful as inhibitors of janus kinases
US20090203718A1 (en) 2006-04-13 2009-08-13 Smithkline Beecham (Cork) Ltd. Cancer treatment method
WO2007119055A1 (en) 2006-04-18 2007-10-25 Astrazeneca Ab Quinazolin-4-one derivatives, process for their preparation and pharmaceutical compositions containing them
MX2008013097A (es) 2006-04-18 2008-10-27 Ardea Biosciences Inc Piridona sulfonamidas y piridona sulfamidas como inhibidores de metiletilcetona.
WO2007123269A1 (ja) 2006-04-19 2007-11-01 Astellas Pharma Inc. アゾールカルボキサミド誘導体
CA2644425A1 (en) 2006-04-19 2007-11-01 Laboratoires Serono S.A. Novel heteroaryl-substituted arylaminopyridine derivatives as mek inhibitors
CN102670605B (zh) 2006-04-20 2015-07-29 詹森药业有限公司 抑制c kit激酶的方法
HUE026820T2 (en) 2006-05-09 2016-07-28 Novaremed Ltd The use of Syk tyrosine kinase inhibitors for the treatment of cell proliferative disorders
CN101443009A (zh) 2006-05-18 2009-05-27 卫材R&D管理有限公司 针对甲状腺癌的抗肿瘤剂
US20090281115A1 (en) 2006-06-30 2009-11-12 Board of Regents, The University of Texas System, a Texas University Inhibitors of c-kit and uses thereof
TW200813021A (en) 2006-07-10 2008-03-16 Merck & Co Inc Tyrosine kinase inhibitors
EP2069020B1 (en) 2006-07-20 2010-01-27 Amgen Inc. Benzo[d]isoxazole derivatives as c-kit tyrosine kinase inhibitors for the treatment of disorders associated with the over production of histamine
AR062207A1 (es) 2006-08-04 2008-10-22 Takeda Pharmaceutical Derivados de imidazopiridazina inhibidores de quinasas utiles para prevenir y/o tratar el cancer.
US20100216791A1 (en) 2006-08-17 2010-08-26 Astrazeneca Pyridinylquinazolinamine derivatives and their use as b-raf inhibitors
JP5274461B2 (ja) 2006-08-18 2013-08-28 アローヘッド リサーチ コーポレイション ポリヌクレオチドのインビボ送達のためのポリ結合体
KR101380444B1 (ko) 2006-08-23 2014-04-01 에자이 알앤드디 매니지먼트 가부시키가이샤 페녹시피리딘 유도체의 염 또는 그 결정 및 이들의 제조 방법
CL2007002617A1 (es) 2006-09-11 2008-05-16 Sanofi Aventis Compuestos derivados de pirrolo[2,3-b]pirazin-6-ilo; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar inflamacion de las articulaciones, artritis reumatoide, tumores, linfoma de las celulas del manto.
ATE531263T1 (de) 2006-09-22 2011-11-15 Pharmacyclics Inc Hemmer der bruton-tyrosinkinase
WO2008045978A1 (en) 2006-10-10 2008-04-17 Rigel Pharmaceuticals, Inc. Pinane-substituted pyrimidinediamine derivatives useful as axl inhibitors
US7977338B2 (en) 2006-10-16 2011-07-12 Novartis Ag Phenylacetamides being FLT3 inhibitors
WO2008047831A1 (fr) 2006-10-17 2008-04-24 Kyowa Hakko Kirin Co., Ltd. Inhibiteurs de JAK
TW200829566A (en) 2006-12-08 2008-07-16 Astrazeneca Ab Chemical compounds
TR201900306T4 (tr) 2006-12-14 2019-02-21 Exelixis Inc Mek inhibitörlerini kullanma yöntemleri.
WO2008076143A1 (en) 2006-12-18 2008-06-26 Osi Pharmaceuticals, Inc. Combination of igfr inhibitor and anti-cancer agent
US7737149B2 (en) 2006-12-21 2010-06-15 Astrazeneca Ab N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof
CA2672172C (en) 2006-12-22 2016-05-03 Astex Therapeutics Limited Bicyclic heterocyclic compounds as fgfr inhibitors
US7879856B2 (en) 2006-12-22 2011-02-01 Rigel Pharmaceuticals, Inc. Diaminothiazoles useful as Axl inhibitors
EP2114954B1 (en) 2006-12-29 2013-02-13 Rigel Pharmaceuticals, Inc. Bicyclic aryl and bicyclic heteroaryl substituted triazoles useful as axl inhibitors
CA2710234C (en) 2006-12-29 2015-10-20 Rigel Pharmaceuticals, Inc. Polycyclic heteroaryl substituted triazoles useful as axl inhibitors
JP5567837B2 (ja) 2006-12-29 2014-08-06 ライジェル ファーマシューティカルズ， インコーポレイテッド Ａｘｌインヒビターとして有用なＮ３−ヘテロアリール置換トリアゾールおよびＮ５−ヘテロアリール置換トリアゾール
JP2010514810A (ja) 2006-12-29 2010-05-06 ライジェル ファーマシューティカルズ， インコーポレイテッド Ａｘｌインヒビターとして有用な置換トリアゾール
PL2114955T3 (pl) 2006-12-29 2013-06-28 Rigel Pharmaceuticals Inc Triazole podstawione mostkowanym bicyklicznym arylem oraz mostkowanym bicyklicznym heteroarylem użyteczne jako inhibitory Axl
EP1944369A1 (en) 2007-01-12 2008-07-16 The Centre National de la Recherche Scientifique Dbait and its standalone uses thereof
ES2547303T3 (es) 2007-01-19 2015-10-05 Ardea Biosciences, Inc. Inhibidores de MEK
WO2008098139A2 (en) 2007-02-07 2008-08-14 The Regents Of The University Of Colorado Axl tyrosine kinase inhibitors and methods of making and using the same
WO2008102870A1 (ja) 2007-02-23 2008-08-28 Eisai R & D Management Co., Ltd. Ｈｇｆｒ遺伝子増幅細胞株に優れた細胞増殖阻害効果および抗腫瘍効果を示すピリジン誘導体またはピリミジン誘導体
CN101622015A (zh) 2007-03-05 2010-01-06 协和发酵麒麟株式会社 药物组合物
SI2152701T1 (sl) 2007-03-12 2016-03-31 Ym Biosciences Australia Pty Ltd Spojine fenil amino pirimidina in njihova uporaba
MX2009010127A (es) 2007-03-22 2009-11-05 Vertex Pharma Compuestos utiles como inhibidores de janus cinasas.
JP5347202B2 (ja) 2007-03-28 2013-11-20 ファーマサイクリックス，インク． ブルトンチロシンキナーゼインヒビター
AU2008240188A1 (en) 2007-04-13 2008-10-23 Supergen, Inc. Axl kinase inhibitors useful for the treatment of cancer or hyperproliferative disorders
UA99459C2 (en) 2007-05-04 2012-08-27 Астразенека Аб 9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer
CL2008001709A1 (es) 2007-06-13 2008-11-03 Incyte Corp Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
GB0714384D0 (en) 2007-07-23 2007-09-05 Ucb Pharma Sa theraputic agents
CA2924436A1 (en) 2007-07-30 2009-02-05 Ardea Biosciences, Inc. Pharmaceutical combinations of n-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide as inhibitors of mek and methods of use
MX2010001244A (es) 2007-07-30 2010-08-31 Ardea Biosciences Inc Derivados de n-(arilamino) sulfonamidas que incluyen polimorfos como inhibidores de mek asi como composiciones, metodos de uso y de preparacion de los mismos.
PA8792501A1 (es) 2007-08-09 2009-04-23 Sanofi Aventis Nuevos derivados de 6-triazolopiridacina-sulfanil benzotiazol y bencimidazol,su procedimiento de preparación,su aplicación como medicamentos,composiciones farmacéuticas y nueva utilización principalmente como inhibidores de met.
WO2009031011A2 (en) 2007-09-05 2009-03-12 Pfizer Limited Xinafoate salt of n4-(2, 2-difluoro-4h-benz0 [1,4] 0xazin-3-one) -6-yl] -5-fluoro-n2- [3- (methylaminocar bonylmethyleneoxy) phenyl] 2, 4-pyrimidinediamine
CA2909988A1 (en) 2007-10-23 2009-04-30 F. Hoffmann-La Roche Ag Kinase inhibitors
CA2703106C (en) 2007-10-24 2015-12-01 Astellas Pharma Inc. Azolecarboxamide derivatives as trka inhibitors
ES2424259T3 (es) 2007-10-26 2013-09-30 Rigel Pharmaceuticals, Inc. Triazoles sustituidos con arilo policíclico y heteroarilo policíclico, útiles como agentes inhibidores del Axl
PL2215094T3 (pl) 2007-11-15 2016-09-30 Związki heterocykliczne zawierające n
US20110039856A1 (en) 2007-11-29 2011-02-17 Pfizer Inc. Polymorphs of a c-met/hgfr inhibitor
EP2240494B1 (en) 2008-01-21 2016-03-30 UCB Biopharma SPRL Thieno-pyridine derivatives as mek inhibitors
GB0801416D0 (en) 2008-01-25 2008-03-05 Piramed Ltd Pharmaceutical compounds
BRPI0907453A2 (pt) 2008-02-01 2015-07-14 Akinion Pharmaceuticals Ab Compostos, uso e preparação dos mesmos
MY158411A (en) 2008-02-05 2016-10-14 Hoffmann La Roche Novel pyridinones and pyridazinones
ATE551342T1 (de) 2008-02-22 2012-04-15 Irm Llc Heterocyclische verbindungen und zusammensetzungen als c-kit- und pdgfr- kinasehemmer
AU2009222144A1 (en) 2008-02-29 2009-09-11 Array Biopharma Inc. Pyrazole [3, 4-b] pyridine Raf inhibitors
PE20091561A1 (es) 2008-02-29 2009-10-30 Array Biopharma Inc Compuestos inhibidores de raf y metodos para su uso
WO2009111277A1 (en) 2008-02-29 2009-09-11 Array Biopharma Inc. Imdizo [4. 5-b] pyridine derivatives used as raf inhibitors
CA2716949A1 (en) 2008-02-29 2009-09-11 Array Biopharma Inc. N- (6-aminopyridin-3-yl) -3- (sulfonamido) benzamide derivatives as b-raf inhibitors for the treatment of cancer
SG191660A1 (en) 2008-03-11 2013-07-31 Incyte Corp Azetidine and cyclobutane derivatives as jak inhibitors
US8822500B2 (en) 2008-03-19 2014-09-02 Chembridge Corporation Tyrosine kinase inhibitors
AU2009226153B2 (en) 2008-03-19 2014-02-20 Chembridge Corporation Novel tyrosine kinase inhibitors
CA2721183C (en) 2008-04-11 2019-07-16 Alnylam Pharmaceuticals, Inc. Site-specific delivery of nucleic acids by combining targeting ligands with endosomolytic components
SG189784A1 (en) 2008-04-14 2013-05-31 Ardea Biosciences Inc Compositions and methods for preparing and using same
AU2009237938A1 (en) 2008-04-16 2009-10-22 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Quinoline derivatives as AXL kinase inhibitors
CN104230911A (zh) 2008-04-16 2014-12-24 波托拉医药品公司 作为syk或jak蛋白激酶抑制剂的2,6-二氨基-嘧啶-5-基甲酰胺类化合物
KR101623997B1 (ko) 2008-04-16 2016-05-24 포톨라 파마슈티컬스, 인코포레이티드 ｓｙｋ 또는 ＪＡＫ 키나제 억제제로서의 ２,６－디아미노－피리미딘－５－일－카르복스아미드
JP2011518219A (ja) 2008-04-22 2011-06-23 ポートラ ファーマシューティカルズ， インコーポレイテッド タンパク質キナーゼの阻害剤
CA2722326A1 (en) 2008-04-24 2009-10-29 Incyte Corporation Macrocyclic compounds and their use as kinase inhibitors
EP3210609A1 (en) 2008-05-21 2017-08-30 Ariad Pharmaceuticals, Inc. Phosphorous derivatives as kinase inhibitors
NZ602791A (en) 2008-05-21 2014-04-30 Incyte Corp Salts of 2-fluoro-n-methyl-4-[7-(quinolin-6-yl-methyl)- imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same
GB0811304D0 (en) 2008-06-19 2008-07-30 Ucb Pharma Sa Therapeutic agents
MX2010014234A (es) 2008-06-19 2011-03-25 Astrazeneca Ab Compuestos pirazol 436.
JP5595389B2 (ja) 2008-06-20 2014-09-24 ジェネンテック， インコーポレイテッド トリアゾロピリジンｊａｋ阻害剤化合物と方法
AU2009259853A1 (en) 2008-06-20 2009-12-23 Genentech, Inc. Triazolopyridine JAK inhibitor compounds and methods
ES2552320T3 (es) 2008-06-24 2015-11-27 F. Hoffmann-La Roche Ag Nuevas piridín-2-onas y piridazín-3-onas sustituidas
JP5592884B2 (ja) 2008-07-09 2014-09-17 ライジェル ファーマシューティカルズ， インコーポレイテッド Ａｘｌ阻害剤として有用な多環式ヘテロアリール置換トリアゾール
ES2399319T3 (es) 2008-07-09 2013-03-27 Rigel Pharmaceuticals, Inc. Triazoles sustituidos con heteroarilos bicíclicos que contienen puentes útiles como inhibidores de AXL
EP3311818A3 (en) 2008-07-16 2018-07-18 Pharmacyclics, LLC Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors
TW201006839A (en) 2008-07-18 2010-02-16 Sanofi Aventis Novel imidazo[1,2-a]pyridine derivatives, process for the preparation thereof, use thereof as medicaments, pharmaceutical compositions and novel use, in particular as MET inhibitors
BRPI0916464A2 (pt) 2008-07-18 2018-06-12 Sanofi-Aventis derivados triazolo(4,3-a) piridina, o respectivo processo de preparo, a respectiva aplicação como medicamentos, composições farmacêuticas e utilização notadamente como inibidores de met
FR2933982A1 (fr) 2008-07-18 2010-01-22 Sanofi Aventis Nouveaux derives imidazo°1,2-a!pyrimidine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de met
KR101651700B1 (ko) 2008-08-04 2016-08-26 메르크 파텐트 게엠베하 신규한 페닐아미노 이소니코틴아미드 화합물
UY32049A (es) 2008-08-14 2010-03-26 Takeda Pharmaceutical Inhibidores de cmet
JP5503655B2 (ja) 2008-09-22 2014-05-28 アレイ バイオファーマ、インコーポレイテッド Ｔｒｋキナーゼ阻害剤としての置換イミダゾ［１，２ｂ］ピリダジン化合物
CN103509017B (zh) 2008-10-22 2015-10-07 阵列生物制药公司 作为TRK激酶抑制剂的取代的吡唑并[1,5-a]嘧啶化合物
MX2011004494A (es) 2008-10-31 2011-05-24 Genentech Inc Compuestos de pirazolopirimidina inhibidores de jak y metodos.
US8598174B2 (en) 2008-11-12 2013-12-03 Genetech, Inc. Pyridazinones, method of making, and method of use thereof
RU2011124894A (ru) 2008-11-19 2012-12-27 Вертекс Фармасьютикалз Инкорпорейтед Триазолотиадиазоловый ингибитор протеинкиназы с-мет
LT2716157T (lt) 2008-12-08 2016-09-12 Gilead Connecticut, Inc. Imidazopirazino syk inhibitoriai
EP2373318B1 (en) 2008-12-08 2019-06-05 Gilead Connecticut, Inc. Imidazopyrazine syk inhibitors
ITMI20082336A1 (it) 2008-12-29 2010-06-30 Univ Parma Composti inibitori irreversibili di egfr con attivita' antiproliferativa
CA2749403A1 (en) 2009-01-13 2010-09-02 Glaxo Group Limited Pyrimidinecarboxamide derivatives as inhibitors of syk kinase
JOP20190231A1 (ar) 2009-01-15 2017-06-16 Incyte Corp طرق لاصلاح مثبطات انزيم jak و المركبات الوسيطة المتعلقة به
CN102281875B (zh) 2009-01-16 2017-09-22 里格尔药品股份有限公司 预防、治疗或应对转移癌的使用axl抑制剂的组合疗法
WO2010085597A1 (en) 2009-01-23 2010-07-29 Incyte Corporation Macrocyclic compounds and their use as kinase inhibitors
FR2941952B1 (fr) 2009-02-06 2011-04-01 Sanofi Aventis Derives de 6-(6-substitue-triazolopyridazine-sulfanyl) 5-fluoro-benzothiazoles et 5-fluoro-benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met.
FR2941951B1 (fr) 2009-02-06 2011-04-01 Sanofi Aventis Derives de 6-(6-nh-substitue-triazolopyridazine-sulfanyl) benzothiazoles et benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met.
AU2010210986A1 (en) 2009-02-09 2011-08-25 Supergen, Inc. Pyrrolopyrimidinyl Axl kinase inhibitors
JP5844727B2 (ja) 2009-03-27 2016-01-20 アルデア バイオサイエンシズ，インコーポレイティド Ｍｅｋ阻害剤としてのジヒドロピリジンスルホンアミド及びジヒドロピリジンスルファミド
KR20120028882A (ko) 2009-04-21 2012-03-23 노파르티스 아게 Ｍｅｋ 억제제로서의 헤테로시클릭 화합물
WO2010126960A1 (en) 2009-04-29 2010-11-04 Locus Pharmaceuticals, Inc. Pyrrolotriazine compounds
CN102482277B (zh) 2009-05-05 2017-09-19 达纳-法伯癌症研究所有限公司 表皮生长因子受体抑制剂及治疗障碍的方法
SMT201900698T1 (it) 2009-05-22 2020-01-14 Incyte Holdings Corp 3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]ottano- o eptano-nitrile come inibitori di jak
EP2441753B1 (en) 2009-06-10 2016-03-30 Chugai Seiyaku Kabushiki Kaisha Tetracyclic compound
TW201103904A (en) 2009-06-11 2011-02-01 Hoffmann La Roche Janus kinase inhibitor compounds and methods
US8377945B2 (en) 2009-06-15 2013-02-19 Rigel Pharmaceuticals Inc. Small molecule inhibitors of spleen tyrosine kinase (SYK)
CN102134218A (zh) 2009-06-15 2011-07-27 凯美隆(北京)药业技术有限公司 6-芳氨基吡啶酮磺酰胺和6-芳氨基吡嗪酮磺酰胺mek抑制剂
TWI462920B (zh) 2009-06-26 2014-12-01 葛萊伯格有限公司 用於治療退化性及發炎疾病之新穎化合物
UA110324C2 (en) 2009-07-02 2015-12-25 Genentech Inc Jak inhibitory compounds based on pyrazolo pyrimidine
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
TW201105669A (en) 2009-07-30 2011-02-16 Irm Llc Compounds and compositions as Syk kinase inhibitors
CN102574847A (zh) 2009-07-30 2012-07-11 Irm责任有限公司 作为syk激酶抑制剂的化合物和组合物
JP2013503190A (ja) 2009-08-28 2013-01-31 アレイ バイオファーマ、インコーポレイテッド Ｒａｆ阻害化合物およびその使用方法
EP2470511A1 (en) 2009-08-28 2012-07-04 Genentech, Inc. Raf inhibitor compounds and methods of use thereof
US20120157452A1 (en) 2009-08-28 2012-06-21 Genentech, Inc. 1h-pyrazolo[3,4-b] pyridine compounds for inhibiting raf kinase
SG178899A1 (en) 2009-08-28 2012-04-27 Array Biopharma Inc Raf inhibitor compounds and methods of use thereof
EP2485589A4 (en) 2009-09-04 2013-02-06 Biogen Idec Inc HETEROARYL-BTK INHIBITORS
DK2473049T3 (en) 2009-09-04 2019-04-01 Biogen Ma Inc INHIBITORS OF BRUTON'S TYROSINKINASE
WO2011039527A1 (en) 2009-09-30 2011-04-07 Merck Sharp & Dohme Ltd Formulations for c-met kinase inhibitors
CA2814617C (en) 2009-10-13 2017-12-19 Allostem Therapeutics Llc Novel mek inhibitors, useful in the treatment of diseases
DK4159217T3 (da) 2009-10-16 2024-08-12 Novartis Ag Kombination, der omfatter en mek-hæmmer og en b-raf-hæmmer
PE20121471A1 (es) 2009-11-04 2012-11-01 Novartis Ag Derivados de sulfonamida heterociclicos utiles como inhibidores de mek
US8735417B2 (en) 2009-12-17 2014-05-27 Merck Sharp & Dohme Corp. Aminopyrimidines as Syk inhibitors
CN102858767B (zh) 2009-12-17 2015-08-19 默沙东公司 作为syk抑制剂的氨基嘧啶
JP5658274B2 (ja) 2009-12-23 2015-01-21 武田薬品工業株式会社 Ｓｙｋ阻害剤としての縮合複素芳香族ピロリジノン
CA2785503A1 (en) 2009-12-23 2011-06-30 Arqule, Inc. Purified pyrroloquinolinyl-pyrrolidine-2,5-dione compositions and methods for preparing and using same
EP2338888A1 (en) 2009-12-24 2011-06-29 Almirall, S.A. Imidazopyridine derivatives as JAK inhibitors
AU2010343102B2 (en) 2009-12-29 2016-03-24 Dana-Farber Cancer Institute, Inc. Type II Raf kinase inhibitors
AR079993A1 (es) 2010-01-12 2012-03-07 Ab Science Derivados de azol, composiciones farmaceuticas y sus usos para tratar trastornos mediados por una sobreactividad de quinasas
WO2011092128A1 (en) 2010-01-29 2011-08-04 Boehringer Ingelheim International Gmbh Substituted naphthyridines and their use as syk kinase inhibitors
NZ602362A (en) 2010-03-11 2014-11-28 Gilead Connecticut Inc Imidazopyridines syk inhibitors
US8481541B2 (en) 2010-03-22 2013-07-09 Hoffmann-La Roche Inc. Pyrrolopyrazine kinase inhibitors
MX345552B (es) 2010-03-24 2017-02-02 Amitech Therapeutic Solutions Inc Compuestos heterocíclicos útiles para inhibición de cinasa.
WO2011121223A1 (fr) 2010-03-30 2011-10-06 Sanofi-Aventis Derives de 6-(alkyl- ou cycloalkyl-triazolopyridazine-sulfanyl) benzothiazoles: preparation, application comme medicaments et utilisation comme inhibiteurs de met
GB201007203D0 (en) 2010-04-29 2010-06-16 Glaxo Group Ltd Novel compounds
US8916593B2 (en) 2010-05-04 2014-12-23 Pfizer Inc. Alkoxy-substituted 2-aminopyridines as ALK inhibitors
US20130072495A1 (en) 2010-05-14 2013-03-21 OSI Pharmaceuticals, LLC Fused bicyclic kinase inhibitors
RU2012152354A (ru) 2010-05-20 2014-06-27 Ф. Хоффманн-Ля Рош Аг Производные пирролопиразина в качестве ингибиторов syk и jak
CN103003281A (zh) 2010-05-20 2013-03-27 弗·哈夫曼-拉罗切有限公司 作为JAK和SYK抑制剂的吡咯并[2，3-b]吡嗪-7-甲酰胺衍生物和它们的用途
EP2576568A1 (en) 2010-05-27 2013-04-10 Vertex Pharmaceuticals Incorporated An aminopyrazole triazolothiadiazole inhibitor of c-met protein kinase
WO2011147764A1 (en) 2010-05-28 2011-12-01 N.V. Organon Thieno (2, 3b) pyrazine compounds as b - raf inhibitors
BR122018011748B1 (pt) 2010-05-31 2021-12-07 Ono Pharmaceutical Co. Ltd Usos de compostos derivados de purinona
PH12012502356A1 (en) 2010-06-03 2013-02-11 Pharmacyclics Llc The use of inhibitors of bruton`s tyrosine kinase (btk)
EA023927B1 (ru) 2010-06-22 2016-07-29 Дна Терапьютикс ОПТИМИЗИРОВАННАЯ С ПОМОЩЬЮ ЭНДОСОМОЛИТИЧЕСКИХ СРЕДСТВ СИСТЕМА ДОСТАВКИ in vivo КОНЪЮГАТОВ НУКЛЕИНОВОЙ КИСЛОТЫ
PL2589592T3 (pl) 2010-06-30 2019-03-29 Fujifilm Corporation Nowe pochodne nikotynamidu lub ich sole
WO2012005299A1 (ja) 2010-07-07 2012-01-12 日本新薬株式会社 Ｒｏｓチロシンキナーゼ阻害剤
WO2012006960A1 (en) 2010-07-14 2012-01-19 Zhejiang Beta Pharma Inc. NOVEL FUSED HETEROCYCLIC DERIVATIVES USEFUL AS c-MET TYROSINE KINASE INHIBITORS
WO2012008564A1 (ja) 2010-07-16 2012-01-19 協和発酵キリン株式会社 含窒素芳香族複素環誘導体
JP5789259B2 (ja) 2010-07-16 2015-10-07 協和発酵キリン株式会社 含窒素芳香族複素環誘導体
AR085183A1 (es) 2010-07-30 2013-09-18 Lilly Co Eli Compuesto 6-(1-metil-1h-pirazol-4-il)-3-(2-metil-2h-indazol-5-iltio)-[1,2,4]triazol[4,3-b]piridazina, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para tratar cancer
UY33539A (es) 2010-08-02 2012-02-29 Astrazeneca Ab Compuestos químicos alk
CN103096716B (zh) 2010-08-10 2016-03-02 西建阿维拉米斯研究公司 Btk抑制剂的苯磺酸盐
CA2808210C (en) 2010-08-20 2019-10-01 Chugai Seiyaku Kabushiki Kaisha Tetracyclic compounds having alk inhibitory activity and compositions thereof
EA201300283A1 (ru) 2010-08-27 2013-08-30 Мерк Патент Гмбх Производные фуропиридина
MX2013002198A (es) 2010-08-27 2013-03-18 Merck Patent Gmbh Derivados de triazolopirazina.
EP2423208A1 (en) 2010-08-28 2012-02-29 Lead Discovery Center GmbH Pharmaceutically active compounds as Axl inhibitors
UY33597A (es) 2010-09-09 2012-04-30 Irm Llc Compuestos y composiciones como inhibidores de la trk
US8664244B2 (en) 2010-09-12 2014-03-04 Advenchen Pharmaceuticals, LLC Compounds as c-Met kinase inhibitors
JO3062B1 (ar) 2010-10-05 2017-03-15 Lilly Co Eli R)-(e)-2-(4-(2-(5-(1-(3، 5-داي كلورو بيريدين-4-يل)إيثوكسي)-1h-إندازول-3-يل)?ينيل)-1h-بيرازول-1-يل)إيثانول بلوري
CN103298803A (zh) 2010-10-08 2013-09-11 艾科睿控股公司 作为激酶抑制剂化合物的取代的哒嗪羧酰胺化合物
TW201238938A (en) 2010-11-01 2012-10-01 Portola Pharm Inc Benzamides and nicotinamides as Syk modulators
CN102020651B (zh) 2010-11-02 2012-07-18 北京赛林泰医药技术有限公司 6-芳基氨基吡啶酮甲酰胺mek抑制剂
CN102532141A (zh) 2010-12-08 2012-07-04 中国科学院上海药物研究所 [1，2，4]三唑并[4，3-b][1，2，4]三嗪类化合物、其制备方法和用途
US20130004481A1 (en) 2011-01-12 2013-01-03 Boehringer Ingelheim International Gmbh Anticancer therapy
AU2012220572A1 (en) 2011-02-25 2013-08-29 Irm Llc Compounds and compositions as trk inhibitors
GB201104153D0 (en) 2011-03-11 2011-04-27 Glaxo Group Ltd Novel compounds
EP2683716A1 (en) 2011-03-11 2014-01-15 Glaxo Group Limited Pyrido[3,4-b]pyrazine derivatives as syk inhibitors
RU2610840C2 (ru) 2011-03-28 2017-02-16 Ф. Хоффманн-Ля Рош Аг Тиазолопиримидины
JP6147727B2 (ja) 2011-04-01 2017-06-14 ユニヴァーシティー オブ ユタ リサーチ ファウンデーション チロシン受容体キナーゼｂｔｋ阻害剤としての置換ｎ−（３−（ピリミジン−４−イル）フェニル）アクリルアミド類似体
BR112013025387B1 (pt) 2011-04-01 2021-07-27 University Of Utah Research Foundation Compostos análogos substituídos da n-fenilpirimidin-2-amina como inibidores da quinase axl, uso dos ditos compostos para o tratamento de um distúrbio de proliferação celular descontrolada, bem como kit compreendendo ditos compostos
UA108926C2 (ru) 2011-04-05 2015-06-25 Пфайзер Лімітед LibreOffice? [2,3-D] +" +" !+
KR20140025500A (ko) 2011-05-04 2014-03-04 머크 샤프 앤드 돔 코포레이션 아미노-피리딘-함유 비장 티로신 키나제 (Syk) 억제제
US9120785B2 (en) 2011-05-10 2015-09-01 Merck Sharp & Dohme Corp. Pyridyl aminopyridines as Syk inhibitors
US9145391B2 (en) 2011-05-10 2015-09-29 Merck Sharp & Dohme Corp. Bipyridylaminopyridines as Syk inhibitors
JP2014513686A (ja) 2011-05-10 2014-06-05 メルク・シャープ・アンド・ドーム・コーポレーション Ｓｙｋ阻害薬としてのアミノピリミジン
SI2712358T1 (sl) 2011-05-13 2017-03-31 Array Biopharma, Inc. Spojine pirolidinil sečnine, pirolidinil tiosečnine in pirolidinil gvanidina kot inhibitorji kinaze trka
EP2527440A1 (en) * 2011-05-27 2012-11-28 Institut Curie Cancer treatment by combining DNA molecules mimicking double strand breaks with hyperthermia
WO2012167423A1 (en) 2011-06-08 2012-12-13 Hutchison Medipharma Limited Substituted pyridopyrazines as novel syk inhibitors
CN102816162B (zh) 2011-06-10 2016-04-27 中国科学院广州生物医药与健康研究院 嘧啶并嘧啶酮类化合物及其药用组合物和应用
CA2833771C (en) 2011-06-10 2021-08-03 Merck Patent Gmbh Compositions and methods for the production of pyrimidine and pyridine compounds with btk inhibitory activity
CN102393896B (zh) 2011-07-11 2014-08-27 成都西谷曙光数字技术有限公司 一种简单精确的射频定位系统和方法
US9102673B2 (en) 2011-07-12 2015-08-11 Merck Sharp & Dohme Corp. Substituted pyrrolo[3,2-c]pyridines as TrkA kinase inhibitors
HUE056249T2 (hu) 2011-07-19 2022-02-28 Merck Sharp & Dohme 4-Imidazopiridazin-1-il-benzamidok és 4-imidazotriazin-1-il-benzamidok mint BTK-inhibitorok
AU2012285988B2 (en) 2011-07-19 2017-05-25 Merck Sharp & Dohme B.V. 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides Btk-inhibitors
EP2548877A1 (en) 2011-07-19 2013-01-23 MSD Oss B.V. 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors
CA2842841C (en) 2011-07-27 2016-04-19 Nanjing Allgen Pharma Co. Ltd. Spirocyclic molecules as protein kinase inhibitors
KR101924247B1 (ko) 2011-07-27 2019-02-22 에이비 사이언스 선택적 프로테인 키나제 저해제로서 옥사졸 및 티아졸 유도체
CN103797011B (zh) 2011-09-01 2016-03-30 诺华股份有限公司 作为c-Kit激酶抑制剂的化合物和组合物
BR112014003963A2 (pt) 2011-09-01 2017-03-21 Irm Llc compostos e composições como inibidores de quinase c-kit
CN104024254A (zh) 2011-09-01 2014-09-03 Irm责任有限公司 作为c-Kit激酶抑制剂的化合物和组合物
US9199981B2 (en) 2011-09-01 2015-12-01 Novartis Ag Compounds and compositions as C-kit kinase inhibitors
EP3332785B1 (en) 2011-09-14 2020-05-06 Neupharma, Inc. Certain chemical entities, compositions, and methods
WO2013047813A1 (ja) 2011-09-30 2013-04-04 大鵬薬品工業株式会社 １，２，４－トリアジン－６－カルボキサミド誘導体
US9216173B2 (en) 2011-10-05 2015-12-22 Merck Sharp & Dohme Corp. 2-Pyridyl carboxamide-containing spleen tyrosine kinase (SYK) inhibitors
WO2013052391A1 (en) 2011-10-05 2013-04-11 Merck Sharp & Dohme Corp. PHENYL CARBOXAMIDE-CONTAINING SPLEEN TYROSINE KINASE (Syk) INHIBITORS
EP2763975B1 (en) 2011-10-05 2016-04-06 Merck Sharp & Dohme Corp. 3-pyridyl carboxamide-containing spleen tyrosine kinase (syk) inhibitors
UA111382C2 (uk) 2011-10-10 2016-04-25 Оріон Корпорейшн Інгібітори протеїнкінази
EA201892766A1 (ru) 2011-10-19 2019-08-30 Фармасайкликс Элэлси ПРИМЕНЕНИЕ ИНГИБИТОРОВ ТИРОЗИНКИНАЗЫ БРУТОНА (Btk)
KR20140095513A (ko) 2011-11-01 2014-08-01 에프. 호프만-라 로슈 아게 이미다조피리다진 화합물
EP2773632B1 (en) 2011-11-03 2017-04-12 F. Hoffmann-La Roche AG 8-fluorophthalazin-1(2h)-one compounds as inhibitors of btk activity
UA111756C2 (uk) 2011-11-03 2016-06-10 Ф. Хоффманн-Ля Рош Аг Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона
EP2773639B1 (en) 2011-11-03 2017-04-26 F. Hoffmann-La Roche AG Alkylated piperazine compounds as inhibitors of btk activity
EP3045453A1 (en) 2011-11-14 2016-07-20 Cephalon, Inc. Uracil derivatives as axl and c-met kinase inhibitors
NZ626750A (en) 2011-11-29 2015-08-28 Ono Pharmaceutical Co Purinone derivative hydrochloride
WO2013088256A1 (en) 2011-12-12 2013-06-20 Dr. Reddy's Laboratories Ltd. Substituted pyrazolo[1,5-a] pyridine as tropomyosin receptor kinase (trk) inhibitors
PL2796460T3 (pl) 2011-12-21 2018-12-31 Jiangsu Hengrui Medicine Co. Ltd. Sześcioczłonowa pirolowa heteroarylowa pochodna pierścieniowa, sposób jej otrzymywania i zastosowania medyczne
RU2576623C2 (ru) 2011-12-28 2016-03-10 Фуджифилм Корпорэйшн Новое производное никотинамида или его соль
US8377946B1 (en) 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
JP6109192B2 (ja) 2012-01-10 2017-04-05 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト ピリダジンアミド化合物及びｓｙｋ阻害剤としてのそれらの使用
KR20140110066A (ko) 2012-01-10 2014-09-16 에프. 호프만-라 로슈 아게 티에노피리미딘 화합물
CN103204825B (zh) 2012-01-17 2015-03-04 上海科州药物研发有限公司 作为蛋白激酶抑制剂的苯并噻唑化合物及其制备方法和用途
CN103204844A (zh) 2012-01-17 2013-07-17 上海艾力斯医药科技有限公司 氨基杂芳基化合物及其制备方法与应用
DK2657233T3 (da) 2012-01-19 2014-09-22 Taiho Pharmaceutical Co Ltd 3,5-disubstitueret alkynylbenzenforbindelse og salt deraf
EP2804861B1 (en) 2012-01-20 2018-02-28 Genosco Substituted pyrimidine compounds and their use as syk inhibitors
JP6006241B2 (ja) 2012-01-31 2016-10-12 第一三共株式会社 ピリドン誘導体
US8501724B1 (en) 2012-01-31 2013-08-06 Pharmacyclics, Inc. Purinone compounds as kinase inhibitors
ES2552518T3 (es) 2012-02-21 2015-11-30 Merck Patent Gmbh Derivados cíclicos de diaminopiridina como inhibidores de Syk
JP6097770B2 (ja) 2012-02-21 2017-03-15 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ フロピリジン誘導体
US9120804B2 (en) 2012-02-21 2015-09-01 Merck Patent Gmbh 8-substituted 2-amino-[1,2,4] triazolo [1, 5-A] pyrazines as Syk tryrosine kinase inhibitors and GCN2 serin kinase inhibitors
WO2013124869A2 (en) 2012-02-21 2013-08-29 Amrita Vishwa Vidyapeetham University The art, method,manner process and system of fibrous bio-degradable polymeric wafers for the local delivery of therapeutic agents in combinations
MX349120B (es) 2012-02-28 2017-07-12 Astellas Pharma Inc Compuesto heterociclico aromatico que contiene nitrogeno.
AP3859A (en) 2012-03-14 2016-10-31 Lupin Ltd Heterocyclyl compounds as MEK inhibitors
RU2673077C2 (ru) 2012-03-15 2018-11-22 Селджен Авиломикс Рисерч, Инк. Твёрдые формы ингибитора киназы рецептора эпидермального фактора роста
BR112014023460B1 (pt) 2012-03-22 2020-09-01 Oscotec, Inc Composto, formulação farmacêutica, uso de um composto
US9365566B2 (en) 2012-03-27 2016-06-14 Takeda Pharmaceutical Company Limited Cinnoline derivatives
CN104321058A (zh) 2012-03-30 2015-01-28 诺华股份有限公司 用于治疗低磷血性疾病的fgfr抑制剂
AU2013243097A1 (en) 2012-04-03 2014-10-09 Novartis Ag Combination products with tyrosine kinase inhibitors and their use
EP2833886B1 (en) 2012-04-04 2020-08-12 HangzhouDeRenYuCheng Biotechnology Ltd. Substituted quinolines as bruton's tyrosine kinase inhibitors
JP5736507B2 (ja) 2012-04-17 2015-06-17 富士フイルム株式会社 含窒素複素環化合物またはその塩
DK2838998T3 (en) 2012-04-18 2018-01-15 Cell Signaling Technology Inc EGFR AND ROS1 IN CANCER
WO2013161919A1 (ja) 2012-04-26 2013-10-31 小野薬品工業株式会社 Ｔｒｋ阻害化合物
JP6114820B2 (ja) 2012-05-14 2017-04-12 イースト チャイナ ユニバーシティ オブ サイエンス アンド テクノロジー プテリジノン誘導体およびｅｇｆｒ、ｂｌｋ、ｆｌｔ３の阻害剤としての応用
WO2013176970A1 (en) 2012-05-22 2013-11-28 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF
GB201209613D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
CN104470918A (zh) 2012-05-30 2015-03-25 日本新药株式会社 芳香族杂环衍生物及医药
TWI585088B (zh) 2012-06-04 2017-06-01 第一三共股份有限公司 作爲激酶抑制劑之咪唑并［１，２－ｂ］嗒衍生物
AR091273A1 (es) 2012-06-08 2015-01-21 Biogen Idec Inc Inhibidores de pirimidinil tirosina quinasa
HUE042374T2 (hu) 2012-06-13 2019-06-28 Incyte Holdings Corp Szubsztituált triciklusos vegyületek mint FGFR inhibitorok
WO2013188184A1 (en) 2012-06-14 2013-12-19 Eli Lilly And Company Inhibitor of jak1 and jak2
WO2013192125A1 (en) 2012-06-20 2013-12-27 Merck Sharp & Dohme Corp. Pyrazolyl derivatives as syk inhibitors
EP2863913B1 (en) 2012-06-20 2018-09-12 Merck Sharp & Dohme Corp. Imidazolyl analogs as syk inhibitors
EP2863915B1 (en) 2012-06-22 2017-12-06 Merck Sharp & Dohme Corp. SUBSTITUTED DIAZINE AND TRIAZINE SPLEEN TYROSINE KINASE (Syk) INHIBITORS
EP2863916B1 (en) 2012-06-22 2018-07-18 Merck Sharp & Dohme Corp. Substituted pyridine spleen tyrosine kinase (syk) inhibitors
TWI520962B (zh) 2012-06-29 2016-02-11 As the c-Met tyrosine kinase inhibitors novel fused pyridine derivatives
CA2782774A1 (en) 2012-07-06 2014-01-06 Pharmascience Inc. Protein kinase inhibitors
WO2014009319A1 (en) 2012-07-11 2014-01-16 Boehringer Ingelheim International Gmbh Indolinone derivatives anticancer compounds
US9725462B2 (en) 2012-08-07 2017-08-08 Merck Patent Gmbh Pyridopyrimidine derivatives as protein kinase inhibitors
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
AP2015008203A0 (en) 2012-08-10 2015-01-31 Boehringer Ingelheim Int Heteroaromatic compounds as bruton's tyrosine kinase (BTK) inhibitors
KR20150042256A (ko) 2012-08-13 2015-04-20 노파르티스 아게 비장 티로신 키나제 (syk)의 억제제로서의 비시클릭 헤테로아릴 시클로알킬디아민 유도체
EP2884982B1 (en) 2012-08-20 2017-09-20 Merck Sharp & Dohme Corp. SUBSTITUTED PHENYL SPLEEN TYROSINE KINASE (Syk) INHIBITORS
KR20150043323A (ko) 2012-08-21 2015-04-22 에프. 호프만-라 로슈 아게 비장 티로신 키나제 억제제로서 피롤로[2,3-b]피라진
CN103122000B (zh) 2012-09-03 2013-12-25 中美冠科生物技术（太仓）有限公司 用作抗肿瘤药物的高选择性的c-Met激酶抑制剂
EP3181567B1 (en) 2012-09-10 2019-03-20 Principia Biopharma Inc. Pyrazolopyrimidine compounds as kinase inhibitors
CA2884921A1 (en) 2012-09-18 2014-03-27 Ziarco Pharma Ltd 2-(2-aminocyclohexyl)amino-pyrimidine-5-carboxamides as spleen tyrosine kinasei(syk) inhibitors
JP5759568B2 (ja) 2012-09-25 2015-08-05 中外製薬株式会社 Ｒｅｔ阻害剤
EP2900243A4 (en) 2012-09-27 2016-04-13 Portola Pharm Inc BICYCLIC OXA LACTAM KINASE HEMMER
WO2014048065A1 (en) 2012-09-28 2014-04-03 Merck Sharp & Dohme Corp. Triazolyl derivatives as syk inhibitors
JP6401169B2 (ja) 2012-10-04 2018-10-03 ユニヴァーシティー オブ ユタ リサーチ ファウンデーション チロシン受容体キナーゼｂｔｋ阻害剤としての置換ｎ−（３−（ピリミジン−４−イル）フェニル）アクリルアミド類似体
WO2014055934A2 (en) 2012-10-04 2014-04-10 University Of Utah Research Foundation Substituted n-(3-(pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase btk inhibitors
CN104955805B (zh) 2012-10-19 2018-11-09 霍夫曼-拉罗奇有限公司 Syk的抑制剂
JP2015535227A (ja) 2012-10-26 2015-12-10 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Ｓｙｋの３，４−二置換１ｈ−ピラゾール及び４，５−二置換チアゾール阻害剤
JP6178861B2 (ja) 2012-11-02 2017-08-09 ファイザー・インク ブルトン型チロシンキナーゼ阻害剤
CN102977014B (zh) 2012-11-05 2015-01-07 沈阳药科大学 新的喹啉类化合物及其用途
EP2916836A4 (en) 2012-11-07 2016-08-03 Merck Sharp & Dohme AMINOPYRIDE-CONTAINING MILK TYROSINE KINASE (SYK) INHIBITOR
WO2014078372A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
US9828360B2 (en) 2012-11-13 2017-11-28 Array Biopharma Inc. Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
US9809578B2 (en) 2012-11-13 2017-11-07 Array Biopharma Inc. Pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trkA kinase inhibitors
DK2922844T3 (en) 2012-11-13 2018-03-05 Array Biopharma Inc N-PYRROLIDINYL, N'-PYRAZOLYL-URINE, THIOURINE, GUANIDINE AND CYANOGUANIDE COMPOUNDS AS TRKA-KINASE INHIBITORS
US9981959B2 (en) 2012-11-13 2018-05-29 Array Biopharma Inc. Thiazolyl and oxazolyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
WO2014078325A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. N-(monocyclic aryl),n'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
US9546156B2 (en) 2012-11-13 2017-01-17 Array Biopharma Inc. N-bicyclic aryl,N'-pyrazolyl urea, thiourea, guanidine cyanoguanidine compounds as TrkA kinase inhibitors
US9969694B2 (en) 2012-11-13 2018-05-15 Array Biopharma Inc. N-(arylalkyl)-N′-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
US9822118B2 (en) 2012-11-13 2017-11-21 Array Biopharma Inc. Bicyclic heteroaryl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
AU2013344656A1 (en) 2012-11-15 2015-06-04 Pharmacyclics Llc Pyrrolopyrimidine compounds as kinase inhibitors
CN103848810A (zh) 2012-11-30 2014-06-11 北京赛林泰医药技术有限公司 鲁顿酪氨酸激酶抑制剂
WO2014086032A1 (en) 2012-12-07 2014-06-12 Hutchison Medipharma Limited Substituted pyridopyrazines as syk inhibitors
EP2931281B1 (en) 2012-12-12 2018-01-17 Merck Sharp & Dohme Corp. Amino-pyrimidine-containing spleen tyrosine kinase inhibitors
EP2934525B1 (en) 2012-12-21 2019-05-08 Merck Sharp & Dohme Corp. Thiazole-substituted aminopyridines as spleen tyrosine kinase inhibitors
US9499519B2 (en) 2012-12-26 2016-11-22 Medivation Technologies, Inc. Fused pyrimidine compounds and use thereof
EP2940014B1 (en) 2012-12-28 2018-09-26 Crystalgenomics, Inc. 2,3-dihydro-isoindole-1-on derivative as btk kinase suppressant, and pharmaceutical composition including same
EP2947084B8 (en) 2013-01-18 2021-03-10 Guangzhou Maxinovel Pharmaceuticals Co. Five-and-six-membered heterocyclic compound, and preparation method, pharmaceutical composition and use thereof
WO2014113942A1 (en) 2013-01-23 2014-07-31 Merck Sharp & Dohme Corp. Btk inhibitors
WO2014113932A1 (en) 2013-01-23 2014-07-31 Merck Sharp & Dohme Corp. Btk inhibitors
US20140206681A1 (en) 2013-01-23 2014-07-24 Ronald M. Kim Btk inhibitors
JP6248948B2 (ja) 2013-02-08 2017-12-20 日産化学工業株式会社 ３環性ピロロピリジン化合物及びｊａｋ阻害剤
JP5954486B2 (ja) 2013-02-19 2016-07-20 小野薬品工業株式会社 Ｔｒｋ阻害化合物
AR094812A1 (es) 2013-02-20 2015-08-26 Eisai R&D Man Co Ltd Derivado de piridina monocíclico como inhibidor del fgfr
WO2014130693A1 (en) 2013-02-25 2014-08-28 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
EP2956454A2 (en) 2013-03-11 2015-12-23 Ignyta, Inc. Solid state forms of a quinazoline derivative and its use as a braf inhibitor
JO3377B1 (ar) 2013-03-11 2019-03-13 Takeda Pharmaceuticals Co مشتقات بيريدينيل وبيريدينيل مندمج
JP6403751B2 (ja) 2013-03-14 2018-10-10 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ５−チアゾールカルボキサミン誘導体及びｂｔｋ阻害剤としてのその使用
WO2014141129A2 (en) 2013-03-14 2014-09-18 Grueneberg Dorre A Novel methods, compounds, and compositions for inhibition of ros
JP6495886B2 (ja) 2013-03-15 2019-04-03 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｂｔｋ阻害剤としての複素環式芳香族化合物
BR112015023878A2 (pt) 2013-03-19 2017-07-18 Merck Sharp & Dohme composto, composição farmacêutica, e, uso de um composto
US9617260B2 (en) 2013-04-02 2017-04-11 Hoffmann-La Roche Inc. Inhibitors of bruton's tyrosine kinase
TWI628176B (zh) 2013-04-04 2018-07-01 奧利安公司 蛋白質激酶抑制劑
US10072298B2 (en) * 2013-04-17 2018-09-11 Life Technologies Corporation Gene fusions and gene variants associated with cancer
MX367878B (es) 2013-04-19 2019-09-10 Incyte Holdings Corp Heterociclos bicíclicos como inhibidores de los receptores del factor de crecimiento de fibroblastos (fgfr).
US9499534B2 (en) 2013-04-26 2016-11-22 Merck Sharp & Dohme Corp. Thiazole-substituted aminopyrimidines as spleen tyrosine kinase inhibitors
WO2014176210A1 (en) 2013-04-26 2014-10-30 Merck Sharp & Dohme Corp. Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors
KR102211310B1 (ko) 2013-05-10 2021-02-03 장쑤 한서 파마슈티칼 캄파니 리미티드 [1,2,4]트라이아졸[4,3-에이]피리딘 유도체, 그의 제조 방법 또는 그의 의학적 용도
RS64591B1 (sr) 2013-05-17 2023-10-31 Incyte Holdings Corp Derivati bipirazola kao inhibitori jak
US9694011B2 (en) 2013-05-21 2017-07-04 Jiangsu Medolution Ltd Substituted pyrazolopyrimidines as kinases inhibitors
CA2912806A1 (en) 2013-05-29 2014-12-04 Cephalon, Inc. Pyrrolotriazines as alk inhibitors
WO2014204263A1 (en) 2013-06-20 2014-12-24 The Asan Foundation Substituted pyridinone compounds as mek inhibitors
TW201534597A (zh) 2013-06-20 2015-09-16 Ab Science 作為選擇性蛋白質激酶抑制劑之苯并咪唑衍生物
HUE040645T2 (hu) 2013-06-26 2019-03-28 Abbvie Inc BTK-inhibitor primer karboxamidok
EP3013798B1 (en) 2013-06-28 2018-06-27 BeiGene, Ltd. Fused tricyclic urea compounds as raf kinase and/or raf kinase dimer inhibitors
EP3016953A4 (en) 2013-07-02 2017-03-01 Pharmacyclics, LLC Purinone compounds as kinase inhibitors
TWI649308B (zh) 2013-07-24 2019-02-01 小野藥品工業股份有限公司 喹啉衍生物
EP3027655B1 (en) 2013-07-30 2019-08-21 Blueprint Medicines Corporation Ntrk2 fusions
AU2014296184B2 (en) 2013-07-31 2017-04-27 Gilead Sciences, Inc. Syk inhibitors
LT3049417T (lt) 2013-07-31 2019-02-11 Merck Patent Gmbh Piridinai, pirimidnai ir pirazinai kaip btk inhibitoriai ir jų panaudojimas
TW201536291A (zh) 2013-08-02 2015-10-01 Cephalon Inc 單獨使用ＡＸＬ／ｃＭＥＴ抑制劑或與其它藥劑組合使用以治療多種癌症之方法
CA2921208C (en) 2013-08-12 2018-02-20 Taiho Pharmaceutical Co., Ltd. Fused pyrimidine compound or salt thereof
US9227969B2 (en) 2013-08-14 2016-01-05 Novartis Ag Compounds and compositions as inhibitors of MEK
US20160361314A1 (en) 2013-08-28 2016-12-15 Novartis Ag Combination of an alk inhibitor and a cdk inhibitor for the treatment of cell proliferative diseases
NZ718728A (en) 2013-09-18 2017-03-31 Beijing Hanmi Pharmaceutical Co Ltd Compound inhibiting activities of btk and/or jak3 kinases
WO2015039333A1 (en) 2013-09-22 2015-03-26 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF
WO2015039334A1 (en) 2013-09-22 2015-03-26 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF
WO2015048662A2 (en) 2013-09-30 2015-04-02 X-Rx Discovery, Inc. Substituted nicotinimide inhibitors of btk and their preparation and use in the treatment of cancer, inflammation and autoimmune disease
EA201690618A1 (ru) 2013-09-30 2016-09-30 Фармасайкликс Элэлси Ингибиторы тирозинкиназы брутона
PL3059227T3 (pl) 2013-10-16 2019-11-29 Fujifilm Corp Sól heterocyklicznego związku zawierającego azot lub jej kryształ, kompozycja farmaceutyczna i inhibitor flt3
HRP20191430T1 (hr) 2013-10-21 2019-11-01 Merck Patent Gmbh Spojevi heteroarila kao inhibitori btk i njihove uporabe
JP6434506B2 (ja) 2013-10-21 2018-12-05 ジェノスコ 置換ピリミジン化合物およびｓｙｋ阻害剤としてのそれらの使用
MX387702B (es) 2013-10-25 2025-03-18 Novartis Ag Compuestos de anillos fusionados biciclicos derivados de piridilo como inhibidores de fgfr4.
RU2667892C2 (ru) 2013-10-25 2018-09-25 Шанхай Хэнжуй Фармасьютикал Ко., Лтд. Производные пиридилкетона, способ их получения и их фармацевтическое применение
JP6493218B2 (ja) 2013-11-08 2019-04-03 小野薬品工業株式会社 ピロロピリミジン誘導体
CN104447640B (zh) 2013-12-02 2016-07-13 北京键凯科技有限公司 3-呋喃基-2-氰基-2-丙烯酰胺衍生物及其制备方法、药物组合物和用途
CN105960404B (zh) 2013-12-05 2019-09-03 药品循环有限责任公司 布鲁顿氏酪氨酸激酶的抑制剂
TWI663159B (zh) 2013-12-10 2019-06-21 美商健臻公司 原肌球蛋白相關之激酶（ｔｒｋ）抑制劑
EP3082809B1 (en) 2013-12-20 2021-01-20 Merck Sharp & Dohme Corp. Btk inhibitors
US9783531B2 (en) 2013-12-20 2017-10-10 Merck Sharp & Dohme Corp. Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors
EP3083560B1 (en) 2013-12-20 2021-10-27 Merck Sharp & Dohme Corp. Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors
US9834554B2 (en) 2013-12-20 2017-12-05 Merck Sharp & Dohme Corp. BTK inhibitors
EP3083559B1 (en) 2013-12-20 2021-03-10 Merck Sharp & Dohme Corp. Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors
UY35898A (es) 2013-12-23 2015-07-31 Gilead Sciences Inc ?compuestos inhibidores de syk y composiciones que los comprenden?.
US9914731B2 (en) 2013-12-26 2018-03-13 Ignyta, Inc. Pyrazolo[1,5-a]pyridine derivatives and methods of their use
EP3099674B1 (en) 2014-01-29 2018-10-24 Boehringer Ingelheim International Gmbh Pyrazole compounds as btk inhibitors
EP3102579B1 (en) 2014-02-03 2019-04-10 Cadila Healthcare Limited Heterocyclic compounds
KR102322338B1 (ko) 2014-02-04 2021-11-05 아스텔라스세이야쿠 가부시키가이샤 디아미노헤테로환 카르복스아미드 화합물을 유효 성분으로 하는 의약 조성물
US9783539B2 (en) 2014-02-27 2017-10-10 Jiangsu Ascentage Biomed Development Inc. Indoloquinolone compounds as anaplastic lymphoma kinase (ALK) inhibitors
EP3116506B1 (en) 2014-03-13 2019-04-17 Merck Sharp & Dohme Corp. 2-pyrazine carboxamides as spleen tyrosine kinase inhibitors
WO2015140051A1 (en) 2014-03-19 2015-09-24 Boehringer Ingelheim International Gmbh Heteroaryl sik inhibitors
EP3122744B1 (en) 2014-03-24 2018-11-07 AB Science Diazaspiroalkaneone-substituted oxazole derivatives as spleen tyrosine kinase inhibitors
WO2015143653A1 (en) 2014-03-26 2015-10-01 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF
WO2015143654A1 (en) 2014-03-26 2015-10-01 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF
WO2015143652A1 (en) 2014-03-26 2015-10-01 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF
CN106164076B (zh) 2014-03-27 2019-03-26 詹森药业有限公司 作为ros1抑制剂的化合物
MX367913B (es) 2014-03-27 2019-09-11 Janssen Pharmaceutica Nv Derivados de 4,5,6,7-tetrahidro-pirazolo[1,5-a]pirimidina y 2,3-dihidro-1h-imidazo[1,2-b]pirazol sustituidos como inhibidores de ros1.
WO2015143692A1 (en) 2014-03-28 2015-10-01 Changzhou Jiekai Pharmatech Co., Ltd. Heterocyclic compounds as axl inhibitors
CN105017256A (zh) 2014-04-29 2015-11-04 浙江导明医药科技有限公司 多氟化合物作为布鲁顿酪氨酸激酶抑制剂
CN105085474B (zh) 2014-05-07 2018-05-18 北京赛林泰医药技术有限公司 鲁顿酪氨酸激酶抑制剂
BR112016023299A8 (pt) 2014-05-14 2021-06-29 Nissan Chemical Ind Ltd composto tricíclico e inibidor de jak, agente preventivo, terapêutico ou de melhoria para doenças contra as quais inibição de jak é eficaz e para artrite reumatoide, medicamento e utilização desses compostos
NZ727418A (en) 2014-05-15 2023-03-31 Array Biopharma Inc 1-((3s,4r)-4-(3-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-3-(2-methylpyrimidin-5-yl)-1-phenyl-1h-pyrazol-5-yl)urea as a trka kinase inhibitor
EP3150592B1 (en) 2014-05-30 2023-08-30 Shanghai Emerald Wellcares Pharmaceutical Co., LTD Alk kinase inhibitor, and preparation method and use thereof
WO2015194764A2 (ko) 2014-06-17 2015-12-23 한국화학연구원 피리미딘-2,4-디아민 유도체 및 이를 유효성분으로 함유하는 항암용 약학적 조성물
EP3157921A1 (en) 2014-06-23 2017-04-26 Dr. Reddy's Laboratories Ltd. Substituted imidazo[1,2-a]pyridine compounds useful for the treatment of pain
TWI690525B (zh) 2014-07-07 2020-04-11 日商第一三共股份有限公司 具有四氫吡喃基甲基之吡啶酮衍生物及其用途
TW201617074A (zh) 2014-07-14 2016-05-16 吉李德科學股份有限公司 Ｓｙｋ（脾酪胺酸激酶）抑制劑
AU2015296215A1 (en) 2014-08-01 2017-03-23 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
JP6618120B2 (ja) 2014-08-06 2019-12-11 塩野義製薬株式会社 ＴｒｋＡ阻害活性を有する複素環および炭素環誘導体
NO2721710T3 (en]) 2014-08-21 2018-03-31
KR101710127B1 (ko) 2014-08-29 2017-02-27 한화제약주식회사 야누스인산화효소 억제제로서의 치환된 N-(피롤리딘-3-일)-7H-피롤로[2,3-d]피리미딘-4-아민
WO2016036796A1 (en) 2014-09-03 2016-03-10 Genzyme Corporation Cyclic urea compounds as tropomyosin-related kinase (trk) inhibitors
CN105524068B (zh) 2014-09-30 2017-11-24 上海海雁医药科技有限公司 氮杂双环衍生物、其制法与医药上的用途
PL3200786T3 (pl) 2014-10-03 2020-03-31 Novartis Ag Zastosowanie pochodnych pirydylowych o skondensowanym układzie bicyklicznym jako inhibitorów fgfr4
NZ729603A (en) 2014-10-06 2022-02-25 Merck Patent Gmbh Heteroaryl compounds as btk inhibitors and uses thereof
EP3205650B1 (en) 2014-10-11 2021-08-04 Shanghai Hansoh Biomedical Co., Ltd. Egfr inhibitor, and preparation and application thereof
CA2965516A1 (en) 2014-10-24 2016-04-28 Bristol-Myers Squibb Company Tricyclic atropisomer compounds
EP3212653A2 (en) 2014-10-30 2017-09-06 Sandoz AG Active acrylamides
CN105085489B (zh) 2014-11-05 2019-03-01 益方生物科技（上海）有限公司 嘧啶或吡啶类化合物、其制备方法和医药用途
EP3221309B1 (en) 2014-11-20 2019-11-13 Council of Scientific and Industrial Research Novel benzimidazole based egfr inhibitors
CN105601573B (zh) 2014-11-24 2021-07-02 中国科学院上海药物研究所 2-氨基嘧啶类化合物及其药物组合物和应用
CA2970181A1 (en) 2014-12-11 2016-06-16 Bayer Pharma Aktiengesellschaft Use of pan fgfr inhibitors and method of identifying patients with cancer eligible for treatment with a pan fgfr inhibitor
EP3233829B1 (en) 2014-12-18 2019-08-14 Pfizer Inc Pyrimidine and triazine derivatives and their use as axl inhibitors
ES2749726T3 (es) 2014-12-25 2020-03-23 Ono Pharmaceutical Co Derivado de quinolina
WO2016106629A1 (en) 2014-12-31 2016-07-07 Merck Sharp & Dohme Corp. Btk inhibitors
WO2016106627A1 (en) 2014-12-31 2016-07-07 Merck Sharp & Dohme Corp. Btk inhibitors
WO2016106623A1 (en) 2014-12-31 2016-07-07 Merck Sharp & Dohme Corp. Benzamide imidazopyrazine btk inhibitors
WO2016106628A1 (en) 2014-12-31 2016-07-07 Merck Sharp & Dohme Corp. Btk inhibitors
WO2016106626A1 (en) 2014-12-31 2016-07-07 Merck Sharp & Dohme Corp. Imidazopyrazine analogs with 3-tertiary carbon substitutions as btk inhibitors
WO2016106624A1 (en) 2014-12-31 2016-07-07 Merck Sharp & Dohme Corp. Tertiary alcohol imidazopyrazine btk inhibitors
WO2016106652A1 (en) 2014-12-31 2016-07-07 Merck Sharp & Dohme Corp. Biarylether imidazopyrazine btk inhibitors
CN104530063B (zh) 2015-01-13 2017-01-18 北京赛特明强医药科技有限公司 喹唑啉并杂环类化合物及其制备方法和作为用于治疗癌症的表皮生长因子受体抑制剂的应用
CN105837576B (zh) 2015-01-14 2019-03-26 湖北生物医药产业技术研究院有限公司 Btk抑制剂
EP3248980B1 (en) 2015-01-20 2023-09-06 Wuxi Fortune Pharmaceutical Co., Ltd Jak inhibitor
BR112017015760A2 (pt) 2015-01-23 2018-03-27 Gvk Biosciences Private Limited inibidores de quinase trka
WO2016123706A1 (en) 2015-02-03 2016-08-11 Trillium Therapeutics Inc. Novel fluorinated derivatives as egfr inhibitors useful for treating cancers
WO2016125186A1 (en) 2015-02-03 2016-08-11 Council Of Scientific & Industrial Research Novel flavone based egfr inhibitors and process for preparation thereof
MX373169B (es) 2015-02-20 2020-04-24 Incyte Holdings Corp Heterociclos bicíclicos como inhibidores de receptores del factor de crecimiento fibroblástico (fgfr).
WO2016161570A1 (en) 2015-04-08 2016-10-13 Merck Sharp & Dohme Corp. Azacarbazole btk inhibitors
WO2016161571A1 (en) 2015-04-08 2016-10-13 Merck Sharp & Dohme Corp. Indazole and azaindazole btk inhibitors
WO2016161572A1 (en) 2015-04-08 2016-10-13 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF
CN107667101B (zh) 2015-04-14 2021-07-30 奎利恩特有限公司 作为tam rtk抑制剂的喹啉衍生物
PL3290418T3 (pl) 2015-04-29 2019-11-29 Wuxi Fortune Pharmaceutical Co Ltd Inhibitory kinaz janusowych (jak)
US9725470B2 (en) 2015-05-28 2017-08-08 Theravance Biopharma R&D Ip, Llc Substituted naphthyridines as JAK kinase inhibitors
ES2822748T3 (es) 2015-05-29 2021-05-04 Wuxi Fortune Pharmaceutical Co Ltd Inhibidor de cinasa Janus
EP3310776A4 (en) 2015-06-02 2019-01-16 Pharmacyclics LLC INHIBITORS OF BRUTON TYROSINE KINASE
CA2987335A1 (en) 2015-06-03 2016-12-08 David Goldstein Bruton tyrosine kinase inhibitors
WO2016192074A1 (en) 2015-06-04 2016-12-08 Merck Sharp & Dohme Corp. Btk inhibitors
EP3313839A1 (en) 2015-06-24 2018-05-02 Principia Biopharma Inc. Tyrosine kinase inhibitors
CA2991020A1 (en) 2015-07-07 2017-01-12 Japan Tobacco Inc. Method for producing 7h-pyrrolo[2, 3-d]pyrimidine derivative and intermediate thereof
US10640495B2 (en) 2015-07-07 2020-05-05 Shionogi & Co., Ltd. Heterocycle derivatives having TrkA inhibitory activity
CA2989651A1 (en) 2015-07-09 2017-01-12 Merck Patent Gmbh Pyrimidine derivatives as btk inhibitors and uses thereof
CA2992317A1 (en) 2015-07-16 2017-01-19 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Aniline pyrimidine derivatives and uses thereof
EA035049B1 (ru) 2015-07-16 2020-04-22 Аррэй Байофарма Инк. СОЕДИНЕНИЯ ЗАМЕЩЕННОГО ПИРАЗОЛО[1,5-a]ПИРИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ RET КИНАЗЫ
WO2017015363A1 (en) 2015-07-20 2017-01-26 Dana-Farber Cancer Institute, Inc. Novel pyrimidines as egfr inhibitors and methods of treating disorders
AU2016296905B2 (en) * 2015-07-23 2018-07-05 Centre National De La Recherche Scientifique Use of a combination of Dbait molecule and parp inhibitors to treat cancer
US10561646B2 (en) 2015-07-24 2020-02-18 Shanghai Haiyan Pharmaceutical Technology Co. Ltd. EGFR inhibitor and pharmaceutically acceptable salt and polymorph thereof, and use thereof
KR101766194B1 (ko) 2015-08-07 2017-08-10 한국과학기술연구원 RET 키나아제 저해제인 신규 3-(이속사졸-3-일)-피라졸로[3,4-d]피리미딘-4-아민 화합물
CN106467541B (zh) 2015-08-18 2019-04-05 暨南大学 取代喹诺酮类衍生物或其药学上可接受的盐或立体异构体及其药用组合物和应用
CN107406431B (zh) 2015-08-20 2020-06-26 上海昂睿医药技术有限公司 吲哚类衍生物及其制备方法和其在医药上的用途
MA41559A (fr) 2015-09-08 2017-12-26 Taiho Pharmaceutical Co Ltd Composé de pyrimidine condensé ou un sel de celui-ci
MX2018003351A (es) 2015-09-16 2018-09-17 Loxo Oncology Inc Derivados de pirazolopirimidina como inhibidores de la btk para el tratramiento de cancer.
EP3144307A1 (en) 2015-09-18 2017-03-22 AB Science Novel oxazole derivatives that inhibit syk
CN106554347B (zh) 2015-09-25 2020-10-30 浙江博生医药有限公司 Egfr激酶抑制剂及其制备方法和应用
WO2017059280A1 (en) 2015-10-02 2017-04-06 The University Of North Carolina At Chapel Hill Novel pan-tam inhibitors and mer/axl dual inhibitors
EP3414234B1 (en) 2015-10-14 2022-06-29 Zibo Biopolar Changsheng Pharmaceutical Co. Ltd. Bruton's tyrosine kinase inhibitors
MX382526B (es) 2015-10-23 2025-03-13 Array Biopharma Inc Compuestos de 2-piridazin-3(2h)-ona 2-aril sustituidas y 2-heteroaril sustituidas como inhibidores de las tirosina quinasas fgfr
MX374605B (es) 2015-11-03 2025-03-06 Theravance Biopharma R&D Ip Llc Compuestos inhibidores de jak quinasa para el tratamiento de enfermedad respiratoria.
CN106699743B (zh) 2015-11-05 2020-06-12 湖北生物医药产业技术研究院有限公司 嘧啶类衍生物及其用途
WO2017077507A1 (en) 2015-11-06 2017-05-11 Acerta Pharma B.V. Imidazopyrazine inhibitors of bruton's tyrosine kinase
BR112018010024A8 (pt) 2015-11-19 2019-02-26 Blueprint Medicines Corp compostos e composições úteis no tratamento de distúrbios relacionados a ntrk
HRP20200561T1 (hr) 2015-11-24 2020-06-26 Theravance Biopharma R&D Ip, Llc Prolijekovi spoja jak inhibitora za liječenje gastrointestinalnih upalnih bolesti
HK1250707B (zh) 2015-12-11 2020-07-03 四川科伦博泰生物医药股份有限公司 氮杂环丁烷衍生物、其制备方法及用途
MX375471B (es) 2015-12-16 2025-03-06 Boehringer Ingelheim Int Compuestos heteroaromaticos como inhibidores de btk.
CN106928231B (zh) 2015-12-31 2021-06-01 合肥中科普瑞昇生物医药科技有限公司 一类新型的egfr野生型和突变型的激酶抑制剂
EP3400216A4 (en) 2016-01-06 2019-08-14 Trillium Therapeutics Inc. NOVEL FLUORINATED QUINAZOLINE DERIVATIVES AS INHIBITORS OF EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR)
SI3402792T1 (sl) 2016-01-11 2022-01-31 Merck Patent Gmbh Derivati kinolin-2-ona
WO2017123695A1 (en) 2016-01-13 2017-07-20 Boehringer Ingelheim International Gmbh Isoquinolones as btk inhibitors
US10662187B2 (en) 2016-01-21 2020-05-26 Zibo Biopolar Changsheng Pharmaceutical Co. Ltd. Bruton's tyrosine kinase inhibitors
US10822339B2 (en) 2016-01-26 2020-11-03 Hangzhou Huadong Medicine Group Biopharmaceutical Co. Ltd Pyrrolopyrimidine five-membered azacyclic derivative and application thereof
CN107021963A (zh) 2016-01-29 2017-08-08 北京诺诚健华医药科技有限公司 吡唑稠环类衍生物、其制备方法及其在治疗癌症、炎症和免疫性疾病上的应用
EP3412663B1 (en) 2016-02-04 2022-09-07 Shionogi & Co., Ltd. Nitrogen-containing heterocycle and carbocycle derivatives having trka inhibitory activity
EP3417861B1 (en) 2016-02-19 2020-09-23 Jiangsu Hengrui Medicine Co., Ltd. Pharmaceutical composition containing jak kinase inhibitor or pharmaceutically acceptable salt thereof
TWI687422B (zh) 2016-02-23 2020-03-11 日商大鵬藥品工業股份有限公司 新穎稠合嘧啶化合物或其鹽
KR102441432B1 (ko) * 2016-03-01 2022-09-07 옹쎄오 Ｄｂａｉｔ 분자의 전신 투여에 의한 암 치료법
CN107151249B (zh) 2016-03-04 2020-08-14 华东理工大学 作为flt3抑制剂的蝶啶酮衍生物及应用
AR107912A1 (es) 2016-03-17 2018-06-28 Blueprint Medicines Corp Inhibidores de ret
CN107286077B (zh) 2016-04-01 2021-04-02 合肥中科普瑞昇生物医药科技有限公司 一种选择性的c-kit激酶抑制剂
WO2017190048A1 (en) 2016-04-29 2017-11-02 X-Chem, Inc. Covalent btk inhibitors and uses thereof
CN112624954A (zh) 2016-05-26 2021-04-09 里科瑞尔姆Ip控股有限责任公司 Egfr抑制剂化合物
CN107759600A (zh) 2016-06-16 2018-03-06 正大天晴药业集团股份有限公司 作为jak抑制剂的吡咯并嘧啶化合物的结晶
EP3476848A4 (en) 2016-06-27 2020-01-15 Hangzhou Rex Pharmaceutical Co., Ltd BENZOFURANE-PYRAZOLE-AMINE PROTEIN KINASE INHIBITOR
WO2018001331A1 (zh) 2016-06-30 2018-01-04 杭州华东医药集团新药研究院有限公司 一种咪唑吡啶胺苯基衍生物及其用途
WO2018002958A1 (en) 2016-06-30 2018-01-04 Sun Pharma Advanced Research Company Limited Novel hydrazide containing compounds as btk inhibitors
EP3481831B1 (en) 2016-07-07 2023-09-06 Daewoong Pharmaceutical Co., Ltd. 4-aminopyrazolo[3,4-d]pyrimidinylazabicyclo derivatives and pharmaceutical composition comprising the same
CN107619388A (zh) 2016-07-13 2018-01-23 南京天印健华医药科技有限公司 作为fgfr抑制剂的杂环化合物
WO2018017983A1 (en) 2016-07-22 2018-01-25 Blueprint Medicines Corporation Compounds useful for treating disorders related to ret
WO2018022761A1 (en) 2016-07-27 2018-02-01 Blueprint Medicines Corporation Substituted cyclopentane-amides for treating disorders related to ret
CN107698593A (zh) 2016-08-09 2018-02-16 南京天印健华医药科技有限公司 作为fgfr抑制剂的杂环化合物
ES2925211T3 (es) 2016-08-16 2022-10-14 Merck Patent Gmbh 2-oxo-imidazopiridinas como inhibidores de BTK reversibles y usos de las mismas
KR102530871B1 (ko) 2016-08-29 2023-05-09 더 리젠츠 오브 더 유니버시티 오브 미시건 Alk 억제제로서의 아미노피리미딘
TW201822764A (zh) 2016-09-14 2018-07-01 美商基利科學股份有限公司 Syk抑制劑
US10111882B2 (en) 2016-09-14 2018-10-30 Gilead Sciences, Inc. SYK inhibitors
CN107840846B (zh) 2016-09-19 2020-11-24 郑州泰基鸿诺医药股份有限公司 一种含嘧啶环的化合物、egfr抑制剂及其应用
CN107840842A (zh) 2016-09-19 2018-03-27 北京天诚医药科技有限公司 炔代杂环化合物、其制备方法及其在医药学上的应用
JP2018052878A (ja) 2016-09-29 2018-04-05 第一三共株式会社 ピリジン化合物
JOP20190077A1 (ar) 2016-10-10 2019-04-09 Array Biopharma Inc مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret
TWI704148B (zh) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
WO2018079759A1 (ja) 2016-10-31 2018-05-03 塩野義製薬株式会社 ＴｒｋＡ阻害活性を有する縮合複素環および縮合炭素環誘導体
KR102686957B1 (ko) 2016-11-08 2024-07-22 주식회사 대웅제약 신규한 피롤로피리미딘 유도체 및 이를 포함하는 약학적 조성물
EP3543239B1 (en) 2016-11-15 2024-11-13 Hangzhou HealZen Therapeutics Co., Ltd. Selective bruton's tyrosine kinase inhibitor and use thereof
CA3044384A1 (en) 2016-11-18 2018-05-24 The Regents Of The University Of Michigan 5,6-dihydro-11h-indolo[2,3-b]quinolin-11-ones as alk inhibitors
CN108101905A (zh) 2016-11-24 2018-06-01 中国科学院上海药物研究所 嘧啶并[5,4-b]吲嗪或嘧啶并[5,4-b]吡呤化合物、其制备方法及用途
US11142535B2 (en) 2016-12-12 2021-10-12 Hangzhou Innogate Pharma Co., Ltd. Heterocyclic compound as Syk inhibitor and/or Syk-HDAC dual inhibitor
WO2018108064A1 (zh) 2016-12-13 2018-06-21 南京明德新药研发股份有限公司 作为第四代egfr激酶抑制剂的螺环芳基磷氧化合物
IL291099B2 (en) 2016-12-15 2024-10-01 Ariad Pharma Inc Aminothiazole compounds as c-kit inhibitors
CN110291081B (zh) 2016-12-15 2023-01-31 阿瑞雅德制药公司 作为c-kit抑制剂的苯并咪唑化合物
CN108250200A (zh) 2016-12-28 2018-07-06 中国科学院上海药物研究所 一种具有Axl抑制活性的化合物及其制备和应用
US11130761B2 (en) 2016-12-29 2021-09-28 Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. Substituted pyrrolo[2,1-f][1,2,4]triazines as FGFR inhibitors
EP3567030B1 (en) 2016-12-30 2022-02-09 Medshine Discovery Inc. Quinazoline compound for egfr inhibition
CN108276410B (zh) 2017-01-06 2021-12-10 首药控股(北京)股份有限公司 一种间变性淋巴瘤激酶抑制剂及其制备方法和用途
CN115737637A (zh) 2017-01-10 2023-03-07 王巍 拉索昔芬调节膜结合雌激素信号的应用及治疗癌症的方法
WO2018136663A1 (en) 2017-01-18 2018-07-26 Array Biopharma, Inc. Ret inhibitors
ES2948194T3 (es) 2017-01-18 2023-09-01 Array Biopharma Inc Compuestos de pirazolo[1,5-a]pirazina sustituida como inhibidores de la cinasa RET
CN106831787B (zh) 2017-01-20 2018-10-23 成都倍特药业有限公司 用作布鲁顿酪氨酸激酶抑制剂的化合物及其制备方法和应用
WO2018145525A1 (zh) 2017-02-08 2018-08-16 中国医药研究开发中心有限公司 吡咯并芳杂环类化合物及其制备方法和医药用途
US10464923B2 (en) 2017-02-27 2019-11-05 Merck Patent Gmbh Crystalline forms of 1-(4-{[6-amino-5-(4-phenoxy-phenyl)-pyrimidin-4-ylamino]-methyl}-piperidin-1-yl)-propenone
WO2018153293A1 (zh) 2017-02-27 2018-08-30 北京赛特明强医药科技有限公司 二噁烷并喹唑啉与二噁烷并喹啉类化合物及其制备方法与应用
CA3054455C (en) 2017-02-27 2021-10-26 Betta Pharmaceuticals Co., Ltd Fgfr inhibitor and application thereof
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
JP7219902B2 (ja) 2017-03-22 2023-02-09 スジョウ・バイジブゴン・ファーマスーティカル・テクノロジー・カンパニー・リミテッド ブルトン型チロシンキナーゼ阻害剤
WO2018187355A1 (en) 2017-04-03 2018-10-11 Health Research Inc. Met kinase inhibitors and uses therefor
CN108721298A (zh) 2017-04-19 2018-11-02 华东理工大学 作为布鲁顿酪氨酸激酶抑制剂的嘧啶并杂环化合物及其应用
CN108727382B (zh) 2017-04-19 2022-07-19 华东理工大学 作为btk抑制剂的杂环化合物及其应用
CN107043366B (zh) 2017-04-25 2020-05-26 中国药科大学 4-氨基嘧啶类化合物、其制备方法及医药用途
CA3061302A1 (en) 2017-04-27 2019-10-23 Mochida Pharmaceutical Co., Ltd. Novel tetrahydronaphthyl urea derivative
AR111495A1 (es) 2017-05-01 2019-07-17 Theravance Biopharma R&D Ip Llc Compuestos de imidazo-piperidina fusionada como inhibidores de jak
WO2018208132A1 (en) 2017-05-12 2018-11-15 Korea Research Institute Of Chemical Technology Pyrazolopyrimidine derivatives, preparation method thereof, and pharmaceutical composition for use in preventing or treating cancer, autoimmune disease and brain disease containing the same as an active ingredient
BR112019024322A2 (pt) 2017-05-22 2020-06-16 F. Hoffmann-La Roche Ag Compostos e composições terapêuticos e métodos de uso dos mesmos
EP3630767A1 (en) 2017-05-22 2020-04-08 H. Hoffnabb-La Roche Ag Therapeutic compounds and compositions, and methods of use thereof
CN107176954B (zh) 2017-06-02 2019-01-11 无锡双良生物科技有限公司 一种egfr抑制剂的药用盐及其晶型、制备方法和应用
CN110678461B (zh) 2017-06-14 2021-08-10 正大天晴药业集团股份有限公司 Syk抑制剂及其使用方法
CN109111446B (zh) 2017-06-22 2021-11-30 上海度德医药科技有限公司 一种具有药物活性的杂芳基化合物
MX2020000135A (es) 2017-06-27 2020-07-22 Janssen Pharmaceutica Nv Nuevos compuestos de quinolinona.
WO2019010295A1 (en) 2017-07-05 2019-01-10 Cs Pharmatech Limited SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF EGFR TYROSINE KINASE
WO2019034009A1 (en) 2017-08-12 2019-02-21 Beigene, Ltd. BTK INHIBITOR WITH ENHANCED DOUBLE SELECTIVITY
AU2018317153B2 (en) 2017-08-15 2021-12-23 Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. FGFR inhibitor and medical application thereof
WO2019034075A1 (zh) 2017-08-15 2019-02-21 南京明德新药研发股份有限公司 Fgfr和egfr抑制剂
WO2019034538A1 (en) 2017-08-18 2019-02-21 Universität Regensburg SYNTHESIS, PHARMACOLOGY AND USE OF NEW FMS FLT3 TYROSINE KINASE 3 (FLT3) SELECTIVE INHIBITORS
CN109400610A (zh) 2017-08-18 2019-03-01 浙江海正药业股份有限公司 吡咯并三嗪类衍生物、其制备方法及其在医药上的用途
KR20200041954A (ko) 2017-08-18 2020-04-22 북경한미약품 유한공사 화합물, 이의 약제학적 조성물, 및 이의 용도 및 응용

Also Published As

Publication number Publication date
CN114364798A (zh) 2022-04-15
EP3942045A1 (en) 2022-01-26
US20220143049A1 (en) 2022-05-12
JP2022526713A (ja) 2022-05-26
WO2020188015A1 (en) 2020-09-24
BR112021018168B1 (pt) 2023-11-28
KR20210142154A (ko) 2021-11-24
AU2020242287A1 (en) 2021-09-02
EA202192575A1 (ru) 2022-01-14
BR112021018168A2 (en]) 2021-11-16
CA3129665A1 (en) 2020-09-24
MX2021009863A (es) 2021-11-12

Similar Documents

Publication Publication Date Title
IL284199A (en) CSF1R inhibitors for cancer treatment
IL282663A (en) BT1718 for use in cancer treatment
IL284856A (en) DBAIT molecule in combination with a kinase inhibitor for cancer treatment
IL290415A (en) Compounds with deuterium for use in cancer treatment
IL288522A (en) Inhibitor of egfr for cancer treatment
IL282270A (en) An Aurora A kinase inhibitor for use in the treatment of neuroblastoma
IL277629A (en) RET inhibitor for use in the treatment of cancer involving a change in RET
GB201905780D0 (en) Cancer therapy
IL282093A (en) Combination therapy for cancer
IL284981A (en) Antagonists to semaphorin-4d for use in cancer therapy
IL283687A (en) usp19 inhibitors and their use for therapeutic purposes
ZA202007955B (en) Ccr5 inhibitor for use in treating cancer
IL276668A (en) Thioredoxin reductase inhibitors for use in the treatment of cancer
PL3801490T3 (pl) Związki do zastosowania w kacheksji nowotworowej
IL286533A (en) Compounds for use in the treatment of adcy5-related dyskinesia
HK40061072A (en) A dbait molecule in combination with kinase inhibitor for the treatment of cancer
HK40078764A (en) Vs-6063 in combination with ch5126766 for the treatment of cancer
PT3813832T (pt) Compostos para utilização na prevenção ou tratamento de cancro
HK40060258A (en) Bt1718 for use in treating cancer
HK40059527A (en) Belantamab mafodotin in combination with pembrolizumab for treating cancer
GB201901368D0 (en) Cancer therapy